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Abstract 
 
The Belgian pharmaceutical sector has been accorded a leading role in the attainment of the R&D 
investment targets which the EU Member States set themselves as part of the Lisbon strategy. To 
gain a better insight into that sector’s research activities, the NBB conducted an ad hoc survey in 
2005, covering pharmaceutical companies active in Belgium in the field of research, production and 
distribution of drugs for human use. The analysis of the information obtained from that survey 
makes up the main body of this working paper. 
 
The survey results do not only confirm the importance of the research activities conducted by 
Belgian establishments, but also indicate the frequent cooperation with other research centres and 
the crucial importance of expertise as a factor influencing the location of such activities in Belgium. 
The breakdown of the survey results by kind of establishment on the basis of the type of activities 
conducted in Belgium reveals further clear differences of emphasis in the nature of the R&D 
activities pursued in Belgium and divergences in the scale of the resources used. 
 
The paper also comprises a number of annexes giving additional information on the sector. More 
particularly, they deal with added value and employment, the indirect effects and profitability of the 




JEL-code :  I18, L65, O3. 
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1 INTRODUCTION 
 
1.1  Aim of the research 
At the Lisbon and Barcelona summits, the European Union countries set themselves the goal of 
becoming the most competitive, knowledge-based society in the world by 2010. In that connection, 
a leading role in Belgium is assigned to the drugs sector. That sector in fact invests heavily in 
research and development (R&D) in both absolute and relative terms
1, because there more than in 
any other branch, successful R&D activities are the key to commercial success. However, the 
current statistics and analyses still shed too little light on numerous aspects concerning the 
investment efforts of the drugs sector. In 2005 the NBB therefore conducted an ad hoc survey 
aimed at gaining a better insight into the R&D processes in the Belgian drugs sector. For the 
purposes of the survey, the sector was defined more specifically as pharmaceutical companies 
active in Belgium in the field of research, production and distribution of drugs for human use. In 
organising the survey, the NBB was assisted by the sector federation, pharma.be, in composing the 
population of firms concerned and formulating the questionnaire. However, the Bank alone was 
responsible for collecting, processing and interpreting the results. 
 
The main body of this report deals with the analysis of the survey results. For the non-specialist 
reader, the annexes provide a brief explanation of the sector from an economic point of view. Apart 
from information on value added, employment, indirect effects and profitability, there is also 
background information on reference reimbursement of drugs. 
 
1.2  Content of the survey form 
The form presented to participants in the ad hoc survey contains different types of questions in 
terms of both content and design
2. 
 
In terms of content, the information obtained by the survey can be divided into three broad subjects. 
The first concerns the general economic characteristics of the firm, such as turnover, exports and 
staff. These data can be used not only to assess the representativeness of the answers and 
determine the weighting coefficients for the (quantitative) questions, but also to ascertain the profile 
of the respondents involved in R&D. The other two subjects covered by the survey concern 
respectively the input and the output of the R&D efforts. In regard to input, the survey does not only 
look at traditional items such as expenditure, the staff deployed, location factors and sources of 
funding, but also tries to obtain a clearer view of the relative importance of the various R&D phases 
for projects developed in Belgium and cooperation with other research centres. 
In the case of output, attention focuses both on the successful projects (patents and marketing) and 
on discontinued projects (reasons for discontinuation). 
 
The questions were designed with the aim of minimising the items calling for precise figures, in 
order to ensure a representative response rate even for such a complex subject as R&D. A number 
of questions were therefore formulated in qualitative terms so that participants only needed to tick 
the items. 
 
                                                       
1  For a general economic overview, see Annex 2. 
2  The full questionnaire and explanatory notes may be found in Annex 1. 2  NBB WORKING PAPER 106 - DECEMBER 2006 
The definitions to which the survey form refers are those devised by the Organisation for Economic 
Cooperation and Development (OECD) in the Frascati Manual for R&D surveys. The period 
covered by the survey runs from 2002 to 2004. However, in so far as the data for the three years 
considered are stable and no clear trends are apparent, the analysis which follows is based on 
averages for the period. 
 
1.3 Sample 
Altogether, letters were sent out to a total of 200 firms. More particularly, this concerned a 
population of firms composed by pharma.be – both members and non-members of the sector 
association - active in the development, production and distribution of drugs for human use in 
Belgium. The initial response rate was worryingly low; eventually, by the end of February 2006, after 
the sending of reminders and postponement of the cut-off date, 64 firms had responded to the 
request for participants, including 28 with R&D activities
3. The analysis which follows will discuss 
only the survey results relating to the latter. 
 
Although at first sight the response rate may still appear low, with a total of 64 response forms, and 
particularly just 28 firms active in R&D, the sample is nevertheless fairly representative. 
 
Measured in terms of "turnover on the Belgian market", these 64 participants represent roughly 80 
p.c. of the sector total published by pharma.be
4; firms active in R&D account for around 67 
percentage points of that figure. On the basis of employment, the sample represents on average 72 
p.c. of all respondents and 65 p.c. of those active in R&D (table 1). 
 
 
TABLE 1  REPRESENTATIVENESS OF THE SURVEY SAMPLE 
All firms 
(64 forms) 
Firms active in R&D  
(28 forms) 
 2002 2003 2004 Average  2002 2003 2004 Average
                 
Belgian market 
turnover (billion €)  2.5  2.6  2.8  2.6 
Belgian market 
turnover  (billion  €)  2.1 2.2 2.3  2.2 
Pc of sector total*  82.3  79.0  79.2  80.1  Pc of sector total*  69.2  66.8  65.1  66.9 
                     
Employment  
(physical units 31/12)  18,522  18,995  19,186  18,901 
Employment  
(physical units 31/12)  16,830  17,261  17,432  17,174 
Pc of sector total(*) (**)  72.9  72.0  70.2  71.7  Pc of sector total(*) (**)  66.2  65.4  63.8  65.1 
               
Sources: IMS, pharma.be, NBB. 
*  See footnote 4.  
**  The total sector employment figures relate to the situation on 30 June. 
 
The Belgian pharmaceutical sector has a strong multinational profile. Although most of the 
pharmaceutical multinationals have a subsidiary in Belgium, they do not all engage in the same 
activities. The sample of firms active in R&D reflects that heterogeneity, as the participants’activities 
come under various activity codes (manufacture of pharmaceuticals (Nacebel code 24.4); wholesale 
                                                       
3  In the rest of the text the terms "branches/establishments” and “firms” are used as synonyms for participants/forms, 
although that is not entirely correct. For instance, there are cases in which a form relates to more than one establishment 
belonging to the same firm, while there are also cases where a form relates only to a firm’s research department. 
4   For completeness, it should be pointed out that the totals published by pharma.be are not confined to members of 
  the sector association. Moreover, the sector concept is broader than that used for the survey, since – unlike the latter – it 
  also concerns activities relating to veterinary medicines and in vitro diagnostics. NBB WORKING PAPER 106 - DECEMBER 2006    3 
of pharmaceutical and chemical products (Nacebel codes 51.46 and 51.55 respectively) and 
research and experimental development on natural sciences and engineering (Nacebel 73.1)). 
 
The type of principal activity – production or distribution – pursued by the Belgian branch of a 
pharmaceutical company has some influence on the scale and nature of the R&D activities which it 
conducts in Belgium
5. The largest firms often prove to be the biggest R&D players, so that the 
average tendencies deduced from the survey results do not provide a representative picture for the 
majority of the participants. In discussing the results of the firms active in R&D it was therefore 
decided to calculate not only the general total, which might mask very divergent situations, but also 
the “peer group” results, thus adding to the usefulness of the survey. On the basis of the general 
economic characteristics (output, export, (basic) research, etc.) indicated by the firms on the survey 
form, and the typology of classes of firms used by the industry association, pharma.be, it is possible 
to identify a number of classes of “similar” firms. 
 
 
TABLE 2  COMPOSITION OF THE R&D SAMPLE BY CLASS OF FIRMS 
Class Description  Number in sample Nacebel 




Firms with production in Belgium destined for export and basic research in 
Belgium  3 24.4 
   2  Firms whose main activity consists of R&D   2  73.1 
         
B    Firms with production in Belgium destined largely for export  2  24.4 
         
C 
  
Firms with production in Belgium (whether or not for own account), destined 
mainly for the Belgian market  2  24.4 
         
D    Firms resorting mainly to outside processing in Belgium  0   
         
E    Firms which engage mainly in importing     
   1  and to a lesser extent exporting  13  51.46+51.55 
   2  and not exporting  6  51.46+51.55 
         
Total  28  
Sources: pharma.be, NBB. 
 
 
The federation divides the pharmaceutical companies into five classes according to the activities 
which they pursue in Belgium. Classes A, B, C and D concern firms manufacturing the majority of 
their products in Belgium; firms in the first three classes produce the goods (largely) themselves, 
whereas those in class D resort (mainly) to subcontractors. Class C is different from A and B in that 
the production is destined primarily for the Belgian market, whereas most of the production in the 
last two classes mentioned is for export; firms in class A are different again in that they engage in 
basic research in Belgium, alongside their production activity. Finally, class E comprises firms which 
engage mainly in distribution in Belgium, and import most of their products. 
 
Table 2 shows the composition of the R&D sample for these five different classes of firms. When 
discussing the survey results, it also proved useful to make a further distinction for some items in 
classes A and E, and this is indicated in the table by sub-classes A1 and A2, and E1 and E2 
(table2). 
                                                       
5  In this connection, see 2.2.4 "Type of R&D activities". 4  NBB WORKING PAPER 106 - DECEMBER 2006 
 
However, it was not possible to analyse the survey results at a lower level of aggregation and/or at 
regional level because that would have breached the confidentiality of the information supplied by 
the individual firms. 
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2  SURVEY RESULTS FOR FIRMS ACTIVE IN R&D 
 
2.1 Economic  characteristics 
2.1.1 Turnover 
 
The total turnover of the R&D sample
6 during the period considered averaged € 5.9 billion. Although 
sales on the domestic market grew slightly faster than those on the foreign market during that 
period, domestic sales still represent a significantly smaller percentage of total turnover, averaging 
€ 2.2 billion
7 (table 3). 
 
TABLE 3  ECONOMIC CHARACTERISTICS OF THE R&D SAMPLE 
 2002 2003 2004 Average 
Turnover (billion €)  5.7  5.9  6.2  5.9 
     of which: Sales on the domestic market  2.1  2.2  2.3  2.2 
       
Exports (billion €)  3.6  3.7  3.9  3.8 
       
Employment (physical units 31/12)  16,830  17,261  17,432  17,174 




The uneven distribution of total turnover across the classes of firms reflects the heterogeneity of the 
Belgian pharmaceutical landscape. The firms producing in Belgium (classes A, B and C) account for 
just seven companies
8 in the sample, but represent 69 p.c. of the turnover, while the distribution 
companies (E) account for the remaining 31 p.c. 
Among the production companies, class A firms clearly predominate, while class C represents a 
virtually negligible percentage of turnover – at least where the sample is concerned (chart 1). 
 
                                                       
6  The sample also includes two firms whose main activity consists of R&D and which therefore have no turnover. They 
are, of course, disregarded in the figures concerning turnover and export calculated below. 
7   For comparison: taking all respondents together, the total turnover averaged € 6.5 billion, comprising 2.6 billion on the 
domestic market and 3.9 billion on the foreign market. 
8  The total comes to nine if the two firms mentioned in footnote 6 are included. 6  NBB WORKING PAPER 106 - DECEMBER 2006 
 
CHART 1  SHARES OF THE CLASSES OF 
FIRMS* IN THE TOTAL 
TURNOVER 
CHART 2  TURNOVER BY ORIGIN OF THE 
DRUGS 
























In view of the degree to which pharmaceutical companies producing in Belgium dominate the total 
turnover of the sample, it is not surprising that this turnover consisted mainly of drugs produced by 
the firms themselves in Belgium. Roughly speaking, almost two-thirds of the drugs sold for human 
use were actually produced in Belgium while over one-third were imported from abroad. Drugs 




TABLE 4  TURNOVER OF THE CLASSES OF FIRMS* BY ORIGIN OF THE DRUGS  
  (percentages of the total per class, averages 2002-2004) 
Class* 
   
Own production in Belgium 
 
Subcontracting in Belgium 
 
Imports from abroad 
   
A (A1)   98  0  2 
B 52  1  47 
C 46  53  1 
Production firms (A+B+C)  90  0.3  10 
        
Distribution firms (E)  0  0.3  100 
        
Total 62  0.3  37 
      
Source: NBB. 
*  For a description of the classes of firms, see table 2. 
 NBB WORKING PAPER 106 - DECEMBER 2006    7 
The breakdown of the turnover of the classes of firms by origin of the drugs reveals wide variations
9. 
Belgian produced drugs account for 0 p.c. in the case of the distribution firms as opposed to 90 p.c. 
for the production firms. Among the production firms, the proportion rises to over 98 p.c. in the case 
of class A, whereas for classes B and C it hovers around 50 p.c. For all classes except C, the rest 
of the turnover concerns drugs imported from abroad. In the case of class C, however, foreign 
imports are negligible at 1 p.c., but this is the only class that makes relatively significant use of 
subcontracting in Belgium, namely 53 p.c. (table 4). 
 
2.1.2 Export 
During the period 2002-2004, the average annual exports of firms in the R&D sample came to 
3.8 billion euro (table 3). 
 
The distribution of those exports among the various classes of firms exhibits far wider divergences 
than in the case of turnover. The production firms account for over 95 p.c. of the total. Class A (A1) 
alone represents over 86 percentage points of that figure, while the remaining 9 percentage points 
come under class B. The relative contribution of class C to exports is consequently negligible. The 
distribution firms together account for barely 5 p.c. of total exports. Furthermore, a single firm is the 
source of three-quarters of that figure. Most of the distribution firms in the R&D sample therefore 
export little or nothing, and are local branches specifically geared to the Belgian market (chart 3). 
 
CHART 3  EXPORT SHARES OF THE 
CLASSES OF FIRMS*  
CHART 5  EXPORTS BY ORIGIN OF THE 
DRUGS 

























The difference between the production and distribution firms in the R&D sample in terms of export 
orientation is very obvious from looking at the export/turnover ratio per class of firms. On the basis 
of that ratio, it is particularly apparent that the overall figure of 63 p.c. masks very different real-life 
situations. 
                                                       
9  The calculations naturally included only those firms which were able to supply data for this breakdown.  8  NBB WORKING PAPER 106 - DECEMBER 2006 
 
CHART 4  EXPORT ORIENTATION PER CLASS OF FIRMS* 















* For a description of the classes of firms, see table 2. 
 
The general picture is greatly influenced by the production firms: exports account for 87 p.c. of their 
turnover, whereas that figure is barely 10 p.c. for distribution firms. Once again, the export 
orientation of the production firms mainly reflects the situation for companies in class A, as that 
class achieves 96 p.c. of its turnover via exports, whereas for companies in class B that figure drops 
to 46 p.c. In terms of export orientation, with a figure of 12 p.c., production firms in class C are then 
on the same level as the exporting distribution firms in class E1 (chart 4). 
 
 
The marked dominance of the production firms, and more particularly class A, in turnover and 
exports naturally explains why no less than 92 p.c. of exports by the R&D sample concern drugs 
produced by the companies themselves in Belgium. The rest of the sample’s exports actually 
concern “transit” since almost all – namely 7.9 percentage points – consist of drugs imported from 
abroad. Drugs produced by subcontractors in Belgium account for a negligible share of exports, at 
0.1 p.c., and that is of course due to the small share of the sector’s total exports represented by 
class C, the only group of firms in the sample which commonly uses subcontractors for production 
in Belgium (chart 5 and table 5). 
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TABLE 5  EXPORTS PER CLASS OF FIRMS* BY ORIGIN OF THE DRUGS  
  (percentages of the total per class) 
Class* 
   
Own production in Belgium 
 
Subcontracting in Belgium 
 
Imports from abroad 
   
A (A1)  98  0  2 
B 88  1  11 
C 54  47  0 
Production firms 
(A+B+C) 97  0.1  3 
      
Distribution firms 
 E (E1)  0  0  100 
      
Total 92  0.1  8 
Source: NBB 
* For a description of the classes of firms, see table 2. 
 
2.1.3 Export  destination 
 
As regards the destination of the exports of the R&D sample, the "rest of the world" is in the lead 
with 47.7 p.c. of the total. “Neighbouring countries” are the second largest export destination, taking 
32.7 p.c. of the drugs exported. Of the remaining exports, namely 19.6 p.c., 13.3 percentage points 
go to the "rest of EU15" and 6.3 percentage points to the "rest of Europe" (chart 6). 
 
CHART 6  EXPORT DESTINATION 





Neighbouring countries Rest of EU15




However, in terms of export destination it must once again be said that the overall percentages 
conceal wide variations in the results for the classes of firms. The overall picture again reflects the 
situation of the production companies, particularly those in class A. 10  NBB WORKING PAPER 106 - DECEMBER 2006 
 
TABLE 6  EXPORT DESTINATION PER CLASS OF FIRMS* 
  (percentages of the total per class, averages 2002-2004) 
Class* 
 
   
Neighbouring 
countries 
   
Rest of EU15 
 
 
Rest of Europe 
 
 
Rest of the world 
 
   
      
A (A1)  25  14  7  53 
B 70  8  1  20 
C 80  0  1  16 
Production firms 
(A+B+C)  29 14  7 50 
        
Distribution firms 
E (E1)  97  2  0  1 
        
Total 33  13  6  48 
        
Source: NBB 
* For a description of the classes of firms, see table 2. 
 
Generally speaking, it can be said that, for the individual classes of firms, there is a trade-off 
between the importance of "neighbouring countries" and the "rest of the world", while the "rest of the 
EU15" and the "rest of Europe" are less important. Thus, in the case of the production companies it 
can be said, in particular, that the more a class of firms focuses on exports, the more global its 
activities; conversely, the less a class of firms is geared to exports, the stronger its focus on 
neighbouring countries. In the case of the distribution firms, no less than 97 p.c. of exports are 
destined for neighbouring countries; the individual companies in the sample often even state that all 
their exports go to this group of countries. In view of the small percentage of their turnover 
represented by exports, the implication must be that "neighbouring countries" often means solely 
the Grand Duchy of Luxembourg (table 6). Finally, for all classes of firms the export destination 
remained decidedly constant over the three-year period considered. 
 
TABLE 7  EXPORT MATRIX: SHARES OF THE CLASSES OF FIRMS* AND DESTINATIONS 
  (percentages of the overall total, averages 2002-2004) 
Class* 
 
   
Neighbouring 
countries 
   
Rest of EU15 
 
 
Rest of Europe 
 
 
Rest of the world 
 




A  (A1)  22 12  6  46 86 
B  6 1 0 2 9 
C  0 0 0 0 0 
E  (E1)  5 0 0 0 5 
       
Total 33  13  6  48  100 
       
Source: NBB 
* For a description of the classes of firms, see table 2. 
 
The data concerning the export volume and destination can be used to construct an overall export 
matrix for the sample by classes of firms and export destinations. This shows that, apart from 
exports by A to the various regions, only exports by classes B and E1 to neighbouring countries 
represent a share of 5 p.c. or more of the overall total (table 7). 
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2.1.4 Overall  staff 
 
The overall staff of the R&D sample averaged over 17 000 employees during the period 2002-2004, 
thus representing 65.1 p.c. of the total for the sector (tables 1 and 3). 
 
During the three-year period considered, firms in the R&D sample recorded a continuous expansion 
in their overall staff, totalling an estimated 3.6 p.c. over the period as a whole. They therefore did 
significantly better than the sector in general, since employment declined by just over 4 p.c. during 
those years. 
 
CHART 7  SHARES OF THE CLASSES OF FIRMS* IN THE OVERALL STAFF 













* For a description of the classes of firms, see table 2. 
 
 
The production firms account for 77.5 p.c. of the overall staff in the sample, with A1 firms alone 
representing 57.1 percentage points of that figure (chart 7). 
The expansion of the overall staff over the period 2002-2004 was a phenomenon common to 
virtually all classes of firms. However, the percentage increase was by far the largest in class A2, 
and to a lesser extent in class C, whereas class A1 recorded the bulk of the increase in absolute 
numbers. 
 12  NBB WORKING PAPER 106 - DECEMBER 2006 
2.2  Input data concerning the R&D activities of Belgian branches 
 
2.2.1 R&D  expenditure 
 
The global figure for the R&D expenditure of the participating firms increased from € 1.4 billion in 
2002 to € 1.6 billion in 2004, representing a rise of 16.7 p.c.  These figures are of the same order of 
magnitude as the data compiled for Belgium by the Federal Science Policy Office, reported to 
Eurostat and the OECD for the purpose of international comparison
10. Bearing in mind that the 
survey analysed here is confined to drugs for human use, whereas the data from the Federal 
Science Policy Office in principle concern all pharmaceutical sector disciplines, i.e. including in vitro 
diagnostics and veterinary medicines, then the R&D sample can be considered complete (chart 8). 
 
 



















Survey figures (in billions of euro, left-hand scale)
Federal Science Policy Office figures (in billions of euro, left-hand scale)
Survey figures in percentages of turnover* (right-hand scale)
 
Sources: NBB, Federal Science Policy Office 
* Excluding expenditure by firms in class A2. 
 
 
On average, the shares of the classes of firms in this total vary widely, as 90.3 p.c. of that 
expenditure is concentrated on the production firms in class A, while the remaining percentage 
consists almost exclusively of expenditure by distribution firms (chart 9). 
 
                                                       
10  The Federal Science Policy Office figures for R&D expenditure concern more particularly ANBERD (Analytical Business 
Enterprise Research and Development) data in which the sectoral allocation of the R&D figures is based on the product 
line level, and the industry-related R&D activities of the R&D service sector are allocated to the corresponding industry. 
In other words, this means that the figures include not only the R&D expenditure of the pharmaceutical firms in 
manufacturing industry, but also that of those firms in the wholesale trade and those belonging to the research and 
development sector.  It should also be pointed out that the figures used here in fact represent the sum of intramural and 
extramural expenditure (for an explanation of these terms, see the explanatory notes to the survey form in Annex 1) by 
the Belgian pharmaceutical sector. This approximation is not entirely correct, since that sum theoretically leads to an 
overestimate of the sector total: external expenditure giving rise to activities by Belgian firms within the sector itself leads 
to double counting, because it is included in the (externally funded) intramural expenditure of the latter firms. However, 
the fact that the total obtained via the survey exceeds the figures from the Federal Science Policy Office appears to 
indicate that such double counting is negligible in practice for the pharmaceutical sector.  NBB WORKING PAPER 106 - DECEMBER 2006    13 
That dominance of class A is naturally connected with the fact that the type of primary activity – 
production or distribution – pursued by the Belgian branch of a pharmaceutical company is bound to 
affect the nature of its R&D activities in Belgium
11. In this connection, the industry federation 
explains that, owing to economies of scale, a multinational company will try to concentrate its R&D 
work and the preparation of active substances (plus the conversion to finished drugs) in one or a 
few branches, generally located in the company’s country of origin. In Belgium, the establishments 
in which these two phases of the drugs process take place in fact belong to Belgian firms or firms of 
Belgian origin which have been taken over by foreign companies. However, some parts of the R&D 
process can be divided among various branches. This applies mainly to the clinical trials, especially 




CHART 9  SHARES OF THE CLASSES OF FIRMS* IN R&D EXPENDITURE 













* For a description of the classes of firms, see table 2. 
 
 
The intensiveness of the R&D efforts – a criterion for this was obtained by relating total R&D 
expenditure to turnover – therefore varies greatly from one class of firms to another. For the 
companies taken as a whole, that figure is just under 25 p.c., and increases slightly over the period 
considered, more precisely from 23.0 p.c. to 24.6 p.c.
13 (chart 8). In the case of firms which also 
engage in basic research (class A), however, the expenditure increases to almost 40 p.c. of 





                                                       
11  In this connection, see 2.2.4. "Type of R&D activities" 
12   pharma.be (2004). 
13   The expenditure of research institutions in group A2 was excluded from this calculation since those institutions do not 
have any real turnover. However, if the R&D expenditure by class A2 is included, the percentage is more than 1 
percentage point higher. 14  NBB WORKING PAPER 106 - DECEMBER 2006 
CHART 10  R&D INTENSIVENESS PER CLASS OF FIRMS*, MEASURED BY 
EXPENDITURE 















Total expenditure Intramural expenditure
 
Source: NBB 
* For a description of the classes of firms, see table 2. 
 
The breakdown of R&D expenditure by type for the sample as a whole presents a very balanced 
distribution between intramural (52 p.c.) and extramural expenditure (48 p.c.)
14 (chart 11). 
 
CHART 11  R&D EXPENDITURE BY TYPE 































                                                       
14 For an explanation of these terms, see the explanatory notes to the survey form in Annex 1. NBB WORKING PAPER 106 - DECEMBER 2006    15 
Within intramural expenditure, labour costs and other current costs account for roughly 44 and 45 
p.c.; capital expenditure is therefore a less significant item, generally speaking, representing the 
remaining 11 p.c.  Roughly one-third of the extramural expenditure is effected in Belgium and two-
thirds in the rest of the world (chart 11). 
 
TABLE 8  R&D EXPENDITURE PER CLASS OF FIRMS* BY TYPE  
  (percentages of the total per class, averages 2002-2004) 
  
In p.c. of intramural 
expenditure 
    



























   
Rest of the 
world 
 
   
A1  48  41 46 13  52  15 85 
A2  54  64 27 10  46  66 34 
A (A1+A2)  49  42 45 13  51  26 74 
B  84  38 59  3  16  99 1 
C  48  99 1 0  52  100 0 
Production firms 
(A+B+C)  49  42 45 13  51  27 73 
             
Distribution firms (E)  84  54 44  2  16  97 3 
             
Total  52  44 45 11  48  33 67 
             
Source: NBB 
* For a description of the classes of firms, see table 2. 
 
 
This general picture is also an accurate reflection of the relative importance of R&D expenditure by 
type for the production firms as a whole; however, in the case of the distribution firms the 
percentages diverge, because these firms spend a much higher percentage, over 80 p.c., on 
intramural research, and within that figure a markedly smaller proportion goes on capital 
expenditure. The production firms in class B, like the distribution firms, present an expenditure 
pattern dominated by intramural expenditure
15 (table 8). 
 
Within the different classes of firms, it is noticeable that labour costs represent a higher proportion 
in the case of type A2 research centres, but also for type C firms. However, this finding must be 
qualified by stating that the relative share of labour costs and other current costs varies very widely 
between individual firms: both range between 0 and 99-100 p.c., which implies that the dividing line 
between the two types of expenditure cannot perhaps always be clearly defined. Conversely, a 
point that emerges clearly from the figures is that the capital expenditure is higher for firms in class 
A, probably because of the higher costs of laboratory equipment for basic research. 
 
As regards external expenditure on R&D, the differences between the individual classes of firms are 
clearer. For instance, distribution firms (class E) and production firms which do not conduct any 
basic research in Belgium (classes B and C), effect that expenditure almost exclusively in Belgium. 
                                                       
15  However, as will become apparent later (see 2.2.4 “Type of R&D activities” and 2.2.6 “Cooperation with other research 
centres”, the dominance of intramural expenditure in R&D budgets for most firms concerned produces a distorted picture 
of the location of the R&D activities. For example, respondents pointed out that extramural expenditure by the Belgian 
establishment is paid for (in part) directly by the parent company, and that a high incidence of cooperation with other 
research centres does not always imply substantial investment volumes. 16  NBB WORKING PAPER 106 - DECEMBER 2006 
In contrast, class A firms spend decidedly more on external research in the rest of the world. Within 
group A, there is a further striking difference between A1 and A2 firms, the latter effecting “only” 
one-third of their external expenditure abroad, while the figure for the former is no less than 85 p.c. 
 
Consequently, if the R&D intensiveness of the classes of firms is assessed on the basis of   
intramural rather than total expenditure, that results in only a very small downward adjustment for 
distribution firms and production firms outside class A. However, for this last class, and - in view of 
its dominance of the sector’s R&D activity- for both the production firms as a whole and the overall 
total, R&D intensiveness is roughly halved if those percentages are calculated only on the basis of 
intramural expenditure (chart 10). 
 
Yet the assessment of the investment efforts of the pharmaceutical sector on the basis of intramural 
expenditure only – this approach being fairly common, particularly for international comparisons of 
R&D investments – does not necessarily give an accurate picture of the value of those investments 
for the domestic economy. On the one hand, external R&D expenditure effected abroad may have a 
pay-back for the local economy if there is a direct link with the local production set-up. Conversely, it 
is sometimes claimed that external R&D expenditure, e.g. with Belgian contract organisations 
(CROs
16 etc.), without the intellectual property rights being retained in the country, creates little 
value for the Belgian economy. However, in that connection it can be said that, in practice, such 
expenditure on research conducted by universities, hospitals, etc. appears to be an important 
source of funding for those institutions, which they in turn can devote to research (especially basic 
research and post-graduate training). An additional social effect is that such research programmes 
enable Belgian patients to gain earlier access to potentially innovative drugs. 
 
 
2.2.2 R&D  staff 
 
The total number of staff employed by survey participants for intramural research averaged around 
4600 units during the period 2002-2004, which is about 500 fewer than the average number of units 
according to the Federal Science Policy Office figures
17. In contrast to this last series, which 
indicates a gradual increase in the R&D staff, the changes in the research staff of the R&D sample 
did not exhibit any clear trend during the period considered: in 2003 the numbers were higher than 
the previous year, but in 2004 they remained more or less constant (chart 12). 
 
 
                                                       
16  Contract Research Organisations (CROs) are commercial firms which focus on setting up, conducting and analysing 
clinical studies for large pharmaceutical companies. 
17  The data relating to R&D staff obtained from the Federal Science Policy Office concern ANRSE (Analytical Researchers, 
Scientists and Engineers). These data are compiled in a manner similar to that described for ANBERD data in 
footnote 10. NBB WORKING PAPER 106 - DECEMBER 2006    17 














Number of R&D staff:survey (left-hand scale)
Number of R&D staff: Federal Science Policy Office (left-hand scale)
Number of R&D staff as a percentage of the overall staff (survey)(right-hand scale)
 
Sources: NBB, Federal Science Policy Office. 
 
Most of the R&D staff in the sample are found in class A firms, which account for 83.3 p.c.; the other 
production firms represent only 2.9 p.c. while the distribution firms together employ 13.8 p.c. of that 
staff (chart 13). 
 
CHART 13  SHARES OF THE CLASSES OF FIRMS* IN THE TOTAL R&D STAFF 













* For a description of the classes of firms, see table 2. 
 
The average number of staff employed on R&D in relation to the total overall staff provides an 
alternative way of measuring R&D intensiveness. For the survey sample as a whole, that figure is 18  NBB WORKING PAPER 106 - DECEMBER 2006 
around 27 p.c., and is thus at much the same level as the R&D intensiveness calculated earlier on 
the basis of expenditure, which came to around 24 p.c.
18 (chart 12). 
 
 
CHART 14  R&D INTENSIVENESS PER CLASS OF FIRMS*, MEASURED BY THE STAFF 

















* For a description of the classes of firms, see table 2. 
 
 
The relative differences in R&D intensiveness for the individual classes of firms ascertained on the 
basis of expenditure are confirmed if the intensiveness is calculated on the basis of the R&D staff. 
According to this last criterion, however, the figures are somewhat closer together, as intensiveness 
comes to 37 p.c. for class A, while for the other classes it ranges between 2 and 16 p.c. (chart14). 
 
The human capital employed can be broken down from two angles, namely according to the 
function or type of work performed by the staff in the course of the R&D activities, and according to 
the highest level of qualification reached, though that approach has its limitations since no account 




                                                       
18  For the calculation of R&D intensiveness on the basis of expenditure, expenditure by firms in class A2 was disregarded 
(see footnote 13). 
19  For a description of the various functions and levels of qualification identified in the survey, see the explanatory notes to 
the survey form in Annex 1. NBB WORKING PAPER 106 - DECEMBER 2006    19 
 
CHART 15  R&D STAFF BY FUNCTION*  CHART 16  R&D STAFF BY LEVEL OF 
QUALIFICATION* 






























*  For a description of the functions, see the explanatory notes 
to the survey form in Annex 1. 
Source: NBB 
*  For a description of the levels of qualification, see the 
explanatory notes to the survey form in Annex 1. 
 
The breakdown of R&D staff by functions shows that the categories "researchers" and "technicians" 
are best represented, with 32 and 31 p.c. respectively. The “other supporting staff” and 
"management" categories account for 23 p.c. and 14 p.c. in that order (chart 15). 
 
TABLE 9  R&D STAFF PER CLASS OF FIRMS* BY FUNCTION AND LEVEL OF 
QUALIFICATION** 









   
Resear-
chers 




















   
Other 
 
A1  11 33 37 18 16 26  39  19 
A2  13 39 11 37  5 75  0  20 
A  (A1+A2)  11 34 34 21 15 28  37  19 
B  13 66  2 20 13 36  48  4 
C  100 0 0 0 0  100  0  0 
Production  firms  (A+B+C)  12 35 33 21 15 29  38  19 
            
Distribution firms (E)  33  7  10  50  15  63  13  8 
            
Total  14 32 31 23 15 32  35  17 
Source: NBB 
*  For a description of the classes of firms, see table 2. 
**  For a description of the functions and levels of qualification, see the explanatory notes to the survey form in Annex 1. 
 20  NBB WORKING PAPER 106 - DECEMBER 2006 
However, the relative importance of these four categories must be interpreted with due caution, as 
the variations in the individual answers appear to indicate that the distinction is subjective. There 
are also a number of clear deviations from the average pattern in the various classes of firms. In the 
distribution firms (class E) the job distribution is clearly dominated by "management" and "other 
supporting staff"- this covers mainly administrative personnel – while in the case of the production 
firms in A2 and B the “technicians” category gives way to “other staff” and “researchers” 
respectively. This is probably to do with the type of R&D activities conducted by the firms 
(themselves). The size of the firm is also a factor which can influence the job breakdown, as is 
illustrated by class C (table 9). 
 
As regards the standard of education of the R&D staff, “university/higher education (long course)” 
and “higher education (short course)” are the ones which occur most frequently. These categories 
respectively account for 32 p.c. and 35 p.c. of the R&D staff, while 15 p.c. hold a doctorate (or the 
equivalent), and the remaining 17 p.c. have a different standard of education (chart 16). 
 
The most striking deviations within the individual classes are a percentage of "university/higher 
education (long course)" which is almost twice as high in the distribution firms and research centres 
in class A2. In the case of the distribution firms, the corollary to that higher percentage is a smaller 
proportion of “higher education (short course)” and “other”, while in the case of the research centres 
it is offset by both the “higher education (short course)” category and – somewhat contrary to 
expectations – the "doctorate" category (table 9). 
 
 
2.2.3 Structural  changes 
 
Since the early 1990s the pharmaceutical sector worldwide has been undergoing a substantial 
wave of restructuring, particularly in the form of mergers and acquisitions. The main motives for the 
amalgamation of pharmaceutical companies are generally given as aspects relating to both 
expenditure and income. Apart from the hoped-for cost cutting by means of economies of scale and 
synergy gains, the effort to achieve a regular flow of income also plays a key role. By using mergers 
and acquisitions to extend the range of existing drugs and the pipeline of molecules in development, 
it is possible to fill gaps in pipeline and cater for the impending expiry of patents on existing drugs. 
That is particularly true if that is a way of achieving a degree of diversification in the market and the 
pipeline products, because pharmaceutical companies traditionally focus on only a small number of 
types of therapy, which naturally implies a risk. 
 
In a study conducted for the European Commission on innovation in the pharmaceutical sector, the 
authors conclude on theoretical grounds that mergers and acquisitions in the drugs sector tend in 
the short term to result in lower expenditure on research and development; they see those 
assumptions borne out empirically and by case studies. One reason for the decline in R&D activities 
might be the elimination of marginal and overlapping research projects
20.  
 
The results of the R&D survey of the Belgian market indicate that, during the period 2002-2004, 23 
p.c. or roughly one-quarter of the respondents had undergone a significant structural change with a 
perceptible impact on their R&D activities. It is noticeable that these companies took a positive view 
of the effects on the R&D activities in the Belgian branches, as 83 p.c. of those who answered ‘yes’ 
                                                       
20  Charles River Associates (2004). NBB WORKING PAPER 106 - DECEMBER 2006    21 
reported an increase in expenditure – the impact on the R&D expenditure was still not entirely clear 
for one repsondent at the time of the survey – and 100 p.c. reported an increase in their research 
staff (table 10). In so far as mergers and acquisitions may have negative consequences in the short 
term for the R&D activities of the group of firms as a whole, this therefore certainly does not appear 
to be at the expense of the Belgian branches
21! 
 
TABLE 10  STRUCTURAL CHANGES AND IMPACT ON R&D  
 
No 
   
Yes 
 
Structural changes in 2002-2004 
(p.c. of  respondents)  77  23 
    
     Reduction Increase 
Impact on expenditure 
(p.c. of those answering ‘yes’)     *  83* 
          
Impact on staff 
(p.c. of those answering ‘yes’)     0  100 
          
Source: NBB 
* In the case of one respondent answering ‘yes’, the effects on expenditure were not yet apparent at the time of the survey. 
 
 
2.2.4  Type of R&D activities  
 
The traditional, input-related R&D indicators, namely expenditure and staff, give only a rudimentary 
picture of the research efforts made by the Belgian pharmaceutical sector, because the R&D 
process in the pharmaceutical sector is highly complex, and the degree to which firms engage in 
such activities may vary widely. To gain a better idea of the research on drugs conducted in 
Belgium, the survey therefore zoomed in on various aspects concerning the type of R&D activities. 
 
For a proper understanding of the survey results, it is recommended that readers unfamiliar with the 
typical pattern of the R&D process in the pharmaceutical sector should first study the box below, 
which gives a brief explanation of the principal stages in the R&D process relating to drugs. 
 
                                                       
21  In the middle of 2006 it emerged that one of the Belgian firms taking part in the R&D survey but not reporting any 
significant structural changes affecting its R&D activities during the three years of the survey was soon to be closed 
down as a result of restructuring within the company. 22  NBB WORKING PAPER 106 - DECEMBER 2006 
 
Box: The drug research and development process 
 




This R&D process comprises various stages, and is generally divided into the basic research phase 









During the basic research phase, new molecules (new active substances) are produced and 
screened. Product development begins once such a new molecule looks promising, and will be 
subjected to further pre-clinical and clinical testing. At that point an application will already be 
submitted for a patent for the molecule in question
23. 
 
The main object of the pre-clinical phase is to check the safety of the candidate drug by both in vitro 
testing and animal testing, before testing it on humans. This phase focuses in particular on the 
therapeutic effects of the substance (pharmacological testing), the physical side-effects 
(toxicological testing) and the metabolism (pharmakinetic testing). 
 
During the clinical research and development, candidate drugs which have successfully passed the 
pre-clinical tests are tested on humans under strict medical supervision. These clinical studies are 
divided into various phases. In phase I the drug is administered to a small group of healthy 
                                                       
22  The various stages in the R&D process do not always follow one another as some stages run simultaneously. 
23  For completeness, it should be said that the "additional protection certificate" (ABC) makes it possible to extend the 
period of protection for a drug by a maximum of 5 years; the patent and the certificate must not be valid for more than 15 
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volunteers, the main aim being to check the safety of the product and to investigate the best dosage 
for administering the drug. The phase II trials are conducted on a small number of selected patients, 
and are intended in particular to evaluate the effectiveness of the candidate drug. The aim of the 
phase III tests is to compare the candidate drug with the standard treatment in terms of 
effectiveness and side effects on large groups of patients. 
 
Finally, before the drug can be placed on the market there are still a number of administrative 
approval procedures to be completed: this concerns the submission of the registration papers 
followed by determination of the price, and possibly the transparency and reimbursement 
procedure. 
 






The time elapsing between the production of a new molecule and the licensing of a drug for market 
launch averages twelve to thirteen years. On average, ten years of that time is spent on the entire 
research and development process, and an average of two to three years on the administrative 




According to the pharmaceutical sector, of the five to ten thousand molecules tested in the pre-
clinical phase, only five proceed to the clinical trial phase; of those five, ultimately only one will be 




Various attempts have already been made to calculate the cost of developing new drugs. The 
pharmaceutical sector itself refers in this connection to the latest study by J.A. DiMasi, which – for 
the year 2000 – arrived at a total cost of € 868 million for the development of a new drug (compared 
to € 149 million and 344 million at 2000 prices for the years 1975 and 1987 respectively). These 
costs take account of both failures and the opportunity costs of the capital invested. Because of this 
last element, and also because the calculations concern new molecules – the most expensive to 
develop – and no account is taken of the tax allowances for research budgets, some observers 
doubt this figure. 
 
 





The survey gathered data on the location and frequency of the activities in the period 2002-2004 for 
each type of drug research, more specifically basic research, and pre-clinical and clinical 
development. Since the questions were qualitative and the participants only had to tick the 
appropriate items, the results are given here in the form of percentages.  
 
As regards the nature of pharmaceutical research in Belgium, the survey results clearly indicate the 
importance of the clinical development phases, as all participants state that they have been active 
in that R&D stage (100 pct.). Conversely, pre-clinical development was the stage in which the 
                                                       
24  This is also known as phase IV of the clinical trials; by convention, however, this phase is not normally included under 
R&D (see Frascati OECD manual);  24  NBB WORKING PAPER 106 - DECEMBER 2006 




However, as was already apparent from the breakdown of R&D expenditure in section 2.1, the 
participants did not pursue all those activities internally. On the contrary, it is noticeable that for all 
stages the percentage of firms with extramural activities is higher than the percentage of firms with 
intramural activities (chart 17). 
 
 
CHART 17  TYPE, FREQUENCY AND LOCATION OF THE R&D ACTIVITIES 

























The survey results also reveal that if a participant is active in a particular research stage and 
location, that situation is generally permanent. This is apparent in chart 17 from the similarity 
between the unweighted and frequency-weighted percentages of participants. For the purpose of 
calculating this last figure, the percentage of participants ticking the option "permanent" was given 
twice the weight of those ticking the option "occasional" when the two were added together; 
consequently, the weighted series reflects not only the relative number of participants which were 
active for the type and location concerned, but also the frequency of that activity
26 (chart 17). 
 
As expected, the breakdown of the survey results into individual classes of firms indicates a number 
of clear differences of emphasis between classes in the R&D activities conducted in Belgium. Thus, 
firms in class A are (almost) permanently active in all R&D stages, both intramurally and 
extramurally. The other production firms, particularly those in classes B and C, were all active in 
intramural and extramural research and clinical development phases, but less permanently so; 
however, pre-clinical development was only an occasional, and extramural occurrence. Finally, in 
the case of the distribution firms the emphasis is clearly on the clinical phases; the other stages 
                                                       
25  The questionnaire made no distinction between basic and applied research. 
26  For completeness it should also be said that the weighted series underwent a further transformation which resulted in the 
figures theoretically ranging from zero – no-one engages in activities of the type and location concerned – to 100 – all 
firms are permanently engaged in activities of that type at that location. NBB WORKING PAPER 106 - DECEMBER 2006    25 
involve only a minority of the firms. The distribution firms also exhibit a marked imbalance in favour 
of extramural activities at all stages (table 11). 
 
 
TABLE 11  TYPE, FREQUENCY AND LOCATION OF THE R&D ACTIVITIES PER CLASS 
OF FIRMS* 













   
EM 
   
IM 
   
EM 
   
IM 
   
EM 
   
A1 100  100  100  100  100  100 
A2 50  50  75  100  75  100 
A (A1+A2)  80  80  90  100  90  100 
B 50  75  0  75  50  100 
C 50  50  0  0  50  50 
Production firms 
(A+B+C)  69 75  56  81  75  94 
Distribution firms (E)  32  47  12  29  56  85 
Total 44  56  26  46  62  88 
Source: NBB 
* For a description of the classes of firms, see table 2. 
 
 
2.2.5  Molecules and projects in development  
 
Apart from qualitative data on the nature of the R&D activities conducted in Belgium, the survey 
also attempted to obtain quantitative information on the importance of the Belgian component of the 
research pipeline. However, the quantitative information obtained by the survey must be treated 
with due caution, for two reasons: various respondents were unable/unwilling to provide the 
information requested, so that the aggregate figures must be regarded as a lower limit; also, the 
absolute figures must, of course, be related to a broader international reference point. But it must be 
emphasised in advance that the European and global data which we have in that connection 
provide only a very rough indication of the importance of drug research in Belgium, since the series 
are not entirely comparable in either conceptual or methodological terms. 
 
At the time of the survey, i.e. during 2005, the number of new molecules being developed by the 
Belgian pharmaceutical sector was at least 478. That figure corresponds more particularly to the 
globalisation of the replies from only 24 respondents
27; if this figure is extrapolated on the basis of 
the company average of 20 molecules, then the total number developed in Belgium comes to over 
500 molecules. 
 
An average of 20 new molecules per Belgian firm seems fairly high when considered in the 
international context, as the Centre for Medicines Research International (CMR) calculated that – 
taking all sizes of firms together - the average size of the (global) development pipeline in the period 
2000-2004 totalled around 25 to 30 new active substances
28. 
 
                                                       
27  In calculating the figures a distinction was made between respondents answering "0" and those leaving a blank; unlike 
the former, the latter were naturally not included for calculating averages, for example. 
28 CMR  (2005). 26  NBB WORKING PAPER 106 - DECEMBER 2006 
Of course, that general average of 20 molecules for the Belgian firms masks variations between 
individual firms. The production firms had, on average
29, a pipeline of 38 molecules, while the   
average for the distribution firms came to 11. 
 
 
CHART 18  AVERAGE NUMBER OF MOLECULES IN DEVELOPMENT IN 2005  







Production firms A+B+C Distribution firms E Total
 
Source: NBB 
* For a description of the classes of firms, see table 2. 
 
 
One result of these differences is that production firms account for 64 p.c. of the total number of 
molecules in the Belgian segment of the pipeline, while the remaining 36 p.c. of molecules are 
being developed by distribution firms. 
 
As regards the allocation of those molecules across the various R&D phases, the survey results 
reveal a number of striking points about Belgian drug research. 
 
For instance, the distribution of the average number of projects in development
30 across the various 
development phases in 2004-2005
31 indicates that the numbers are higher for the later R&D 
phases: in particular, there were 116 projects in the pre-clinical phases, compared to 133, 188 and 
263 projects in the respective clinical phases (chart 20). 
 
                                                       
29  It is not possible to provide any further breakdown by classes within the production firms without impairing the 
confidentiality of the figures.  
30  A "project in development" means the development of a molecule for a medical indication and form of administration. 
The number of projects in development therefore need not correspond to the number of new molecules in development, 
since the latter may give rise to multiple projects (e.g. various forms of administration). However, double counting of the 
total number of projects in development cannot be entirely ruled out, since studies may proceed simultaneously in 
various phases. 
31  In view of the low response rate for the years 2002 and 2003, no data are published for those years. NBB WORKING PAPER 106 - DECEMBER 2006    27 
 
CHART 19  NUMBER OF PROJECTS IN DEVELOPMENT IN THE VARIOUS R&D PHASES 

















Such a distribution appears atypical for the sector. The international data on the phase distribution 
available to us, namely the products in development in the European countries, and the worldwide 
data (though the latter concern only the number of new molecules in development) indicate that 
phase III of the clinical research actually comprises the smallest number of products or new 
molecules
32. Another striking point emerges if the figures from the survey are compared with the 
European data (by referring to “products in development”, these appear to use a broader definition  
which is more appropriate to the survey concept): the pre-clinical research conducted here is not 
very significant, in accordance with the survey’s findings in section 2.2.4 "Type of R&D activities". 
The number of projects in phases I and II of the clinical research in Belgium roughly corresponds to 
one-third of the number of products for Europe, but in the case of phase III the Belgian figures are 
slightly above those for Europe. Although attention must be drawn to the precarious character of 
this comparison
33, it does point to the relative importance of clinical research in Belgium, especially 
in the case of phase III. 
 
                                                       
32  These data were obtained from IMS and Pharmaprojects, being cited in CRA(2004) and CMR(2005) respectively. 
33  The figures for Europe concern the year 2003, while the survey results refer to the average for 2004 and 2005.  There is 
also a methodological difference in that each "product" is counted only once for the European data, namely in the latest 
phase of the studies, while in the survey results double counting cannot be entirely ruled out. There could also be some 
conceptual differences between the two series.  28  NBB WORKING PAPER 106 - DECEMBER 2006 
 
CHART 20  SHARES OF THE CLASSES OF FIRMS* IN PROJECTS IN DEVELOPMENT 












Pre-clinical Clinical I Clinical II Clinical III
A1 A2 B C E
 
Source: NBB 
* For a description of the classes of firms, see table 2. 
 
The atypical phase distribution for Belgium is of course connected with the fact that not all Belgian 
firms are active in every R&D phase. The total number of projects in development in Belgium 
therefore conceals a marked difference between the production firms and the distribution firms. In 
the case of the former, the total number of projects in development declines the later the stage in 
the development process, whereas for the latter the situation is precisely the reverse. This 
phenomenon is, of course, reflected in the shares represented by the various groups in the number 
of projects in the various development phases (chart 20). 
 
 
According to the survey results, the overall number of clinical tests conducted on test subjects in 
Belgium in connection with projects in development averaged 495 per annum in the period 2004-
2005. However, this figure must once again be interpreted as a lower limit, because in reality the 
total number of tests in Belgium is probably a great deal higher than could be ascertained by the 
survey
34. Various participants state that the figures on clinical testing could not be given in full. For 
instance, it is quite common for the R&D activities to be organised by the foreign head office for the 
whole European region; for example, if the Belgian branch is not involved in the use of contract 
organisations (CROs, etc.) in Belgium, it will often not have precise information on the tests carried 
out.  
 
The distribution firms accounted for the majority of the total number of tests, at 71.5 p.c. That share 
is due purely to their numerical dominance, as the average number of tests conducted remained 
fairly constant across almost all classes of firms, totalling around 27 tests per year. 
 
The total number of test subjects involved in these clinical tests in Belgium can be estimated at a 
minimum of 100,000 per annum, according to the survey results; on average, this represents 
                                                       
34  The total of 495 tests is the aggregate for "only" 18 respondents. If this figure is extrapolated on the assumption that the 
other participants represent an average of around 27 tests, the actual total could be as high as 700 to 750. NBB WORKING PAPER 106 - DECEMBER 2006    29 
around 200 persons per test. That average masks considerable diversity within the individual 
responses, ranging from a few dozen to several hundred or thousands per test. The number of test 
subjects involved in any clinical test naturally depends on the specific clinical phase in which the 
test is conducted. However, the survey contained no details on this.  
 
 
2.2.6  Cooperation with other research centres 
 
Much of the drug research by Belgian branches in the period 2002-2004 was conducted extra 
muros. The survey ascertained the types of research centres involved in such cooperation and the 
frequency with which it occurred. In addition, a distinction was made between Belgian and foreign 
research centres, in order to detect any differences in the patterns of cooperation. 
 
The participants’ replies to this qualitative question revealed that those using other research centres 
addressed themselves to various types of partners, and did generally not confine themselves to 
partners in Belgium. However, some variation was apparent in the frequency of cooperation. For 
ease of analysis and to permit a ranking of the types of research centres, the participants’ 
qualitative responses were therefore processed into weighted percentages, in the same way as 





CHART 21  COOPERATION WITH OTHER RESEARCH CENTRES IN BELGIUM 

























The Belgian research centres with which the pharmaceutical sector collaborates can be divided into 
two groups. First there are the hospitals, universities and suppliers (contract research institutions): 
not only do the majority of the participants work jointly with these
36, the cooperation is generally also 
frequent. The fact that these types of research centres clearly rank first is due to the importance of 
                                                       
35  In this connection, see 2.2.4 “Type of R&D activities”. 
36  It is worth mentioning that all 26 participants responding to this survey question ticked cooperation with universities.  30  NBB WORKING PAPER 106 - DECEMBER 2006 
clinical development in the R&D activities undertaken by Belgian branches, although the 
cooperation with universities naturally also occurs in the case of basic research. Conversely, far 
fewer respondents ticked “other pharmaceutical firms” – either within the same group or from 
another group – and biotechnology firms, and the cooperation with these types of research centre 
tended to be occasional. “Other” research centres also appeared to belong to this second group of 
less widespread and less frequent partners. One respondent specified that this cooperation took 
place in the field of data management (chart 21). 
 
In the case of cooperation with foreign research centres, the picture is slightly different, as the 
percentages for suppliers, universities and hospitals are a little lower than for joint projects 
conducted in Belgium. In contrast, in the case of international cooperation, pharmaceutical firms, 
particularly those from within the same group (contact with research departments located 
elsewhere), and to a lesser extent pharmaceutical firms from other groups and biotechnology firms 
come to the fore. There was no cooperation at all with “other” foreign partners (chart 22). 
 
 
CHART 22  COOPERATION WITH OTHER RESEARCH CENTRES ABROAD 


























The advance of biotechnology in research methods has led to a worldwide trend towards increasing 
numbers of joint R&D projects in the pharmaceutical sector, e.g. in the form of licensing agreements 
between the pharmaceutical and the biotech sectors. For firms in the pharmaceutical sector, this 
cooperation is part of a new strategy for developing a pipeline of new products. However, the 
importance of such development in global research on drugs
37 is not, at first sight, fully reflected in 
the survey results. There are various possible reasons for this. Cooperation with biotech firms was 
perhaps not always classified as such in the survey. On the one hand, a number of major (Belgian) 
biotech firms are part of their own group of companies and were perhaps regarded as such, while 
on the other hand various biotech firms are set up as spin-offs of university research
38 and may be 
counted among “universities”. Moreover, cooperation with biotech firms may be organised and 
                                                       
37  According to data from EFPIA, around one-fifth of the new molecules launched on the world market each year and half of 
all the drugs in development now come from biotechnology. 
38  In this connection, see FPS Economy (2006) for Belgium. NBB WORKING PAPER 106 - DECEMBER 2006    31 
coordinated from the head office and/or the central R&D department, so that the Belgian branches 
of most companies are not directly involved. The higher percentage for foreign biotech partners 
than for Belgian partners could reflect the continuing lead maintained by the US in this sphere. 
 
Finally, although the survey results indicate that cooperation with other research centres is a 
widespread phenomenon, and those joint projects are often frequent, one respondent pointed out 
that in terms of the investment volume or the number of staff involved in such cooperation, those 
contacts are not always equally significant. Moreover, joint projects do not always come under the 
actual outsourcing of pharmaceutical R&D activities, but also concern a joint search for 
technological solutions with specialist suppliers. 
 
 
2.2.7 Location  factors 
 
Although the Belgian pharmaceutical sector did not escape the general shift in pharmaceutical R&D 
activities from Europe to the US, it still puts in a decidedly substantial R&D effort in regard to other 




Not only do a number of firms in Belgium pursue significant activities in the field of basic research, 
the Belgian pharmaceutical sector has also built up a worldwide reputation for clinical research. 
However, the opportunities for Belgian corporate subsidiaries in attracting/retaining those research 
activities depend on the Belgian investment climate. 
 
That climate is influenced by many different factors; apart from government incentives, aspects 
which may play a role are among others the location of experts, including networks of scientists, 
laboratories, universities and R&D suppliers, and price regulation. Various authors
40 also mention 
the strong interaction between the location of R&D and the drug reimbursement system. They argue 
that more investment can be expected in countries where drugs gain quicker access to the market 
and where there are fewer price restrictions (the price in the country of development being taken as 
the reference price), so that higher profits can be achieved.  
 
The survey attempted to provide an idea of the importance of various factors for the location of 
pharmaceutical research in Belgium. The possible factors were ranked under the headings Human 
Resources (  in chart 23), geographical location ( ), government ( ), market situation ( ) and 
“other” to be defined in more detail ( ). Taking account of the degrees of importance assigned to 
each factor by the respondents, the results for each item were summarised in the form of an index 
which may range, in theory, from -100 (all respondents assess the factor as highly negative) to 
+100 ( all respondents assess the factor as highly positive)
41 (chart 23). 
 
                                                       
39  In this connection, see Annex 2. 
40  e.g. Charles River Associates (2004). 
41   More specifically, the percentage of replies for each degree of importance was taken as the basis for each sub-heading. 
A net percentage was calculated for each factor – i.e. the “negative” percentages were deducted from the “positive” 
percentages, the “highly positive” and “highly negative” percentages being given twice the weighting in the total 
compared to the “moderately positive” and “moderately negative”. For ease of interpretation, care was taken to ensure 
that the net percentage obtained could range in theory from – 100 (all firms assess the factor concerned as highly 
negative) to + 100 (all firms assess the factor concerned as highly positive), in the same way as described in section 
2.2.4 "Type of R&D activities". 32  NBB WORKING PAPER 106 - DECEMBER 2006 
 
CHART 23  ASSESSMENT OF LOCATION FACTORS 
  (balances of the weighted percentages of "positive" and "negative") 
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The item which stands out as the most important in the ranking of the location factors is the 
availability of skilled staff; that factor was not assessed as negative by any of the firms. However, 
some participants did specify that the calibre of the staff was an advantage, but the availability or 
quantity was sometimes inadequate. 
Conversely, the HR factor “labour costs” was assessed as decidedly negative. The trend towards 
relocation in the pharmaceutical sector, by means of contract organisations, transferring clinical 
trials to low wage countries such as Eastern Europe and India therefore represents a genuine threat NBB WORKING PAPER 106 - DECEMBER 2006    33 
to Belgium’s leading position here, especially as those countries have other advantages as well
42.  
As implied by the index figures calculated, however, this factor – taking all firms together
43 - does 
not currently entirely outweigh the first factor, namely the knowledge and expertise available here.  
 
Belgium’s geographical location is regarded as an advantage, as all factors under this heading were 
assessed as positive. However, it is noticeable that, for the pharmaceutical sector, it is not so much 
the central location in Europe that matters – as half of the individual firms gave a neutral response 
on this – but mainly the availability of the infrastructure and the proximity of knowledge  centres and 
suppliers. Conversely, the proximity of other group branches is a far less important factor in the 
location of research activities, a result which is in line with the findings concerning cooperation with 




44 and elements connected with the market situation are assessed as the most 
neutral, though it can be said that within this last group of factors, sales prospects are assessed 
somewhat more favourably than competition conditions. 
 
The survey results also indicate a number of clear points for policymakers, as the factors relating to 
the government are almost all assessed as decidedly negative. The only exception to that adverse 
appraisal applies to the factor "legislation concerning research and pre-clinical trials”. The fact is 
that the Belgian legislature, aware of Belgium’s key position as a host country for clinical trials, 
endeavoured to safeguard Belgium’s competitive position when transposing the European directive 
on clinical trials into Belgian law, by creating an attractive framework. Thus, the periods for granting 
a licence to conduct such tests – 15 and 18 days respectively for mono-centre and multi-centre 
testing – are among the shortest in Europe
45.  However, it appears that the law is still not being 
implemented efficiently. In practice, the deadlines for granting approval for testing are not always 
respected; for example, objections are often not raised until after expiry of the statutory time limit, 
which of course leads to confusion and legal uncertainty. 
 
The negative assessment of the factor "administrative procedures" is perhaps equally to do with the 
effective deadlines. Although maximum periods of time are laid down within the EU in regard to the 
registration of drugs, pricing and possible reimbursement, not only are those periods exceeded in 
practice in Belgium, the time taken also seems to be very long compared with that in other 
countries
46. The decision to set up the Federal Agency for Drugs and Health Products, which will 
supervise the entire drugs process from research to usage, may be a step in the right direction.  
 
The subsidy policy and the fiscal policy pursued by the government directly and indirectly in regard 
to R&D is also assessed as negative by the participants
47. Nevertheless, in the past both the federal 
                                                       
42  For these countries, their larger population is an advantage, especially in the case of the rarer disorders. Moreover, 
patients in these countries tend to be "under medicated", which reduces the risk of interactions between different drugs 
and distortion of the research results. 
43  For completeness, it should be pointed out that the replies of the individual firms were not weighted for the purpose of 
calculating the total. 
44  The item "other" was seldom ticked, and only specified in exceptional cases ("historical links"). The individual 
assessments range from moderately negative to highly positive. When answering the question, the firms may have had a 
variety of factors in view, so that the overall balance is difficult to interpret. 
45 Trouet  (2004). 
46  Cambridge Pharma Consultancy (Dec 2002) remarks in this connection: " Patients in Belgium on average wait 2 years 
longer to receive new medicines than patients in the UK and Germany (...). These delays are usually attributable to 
extended reimbursement negotiations". 
47  It should be remembered that the survey was conducted during 2005, i.e. before there was any more selective levy on 
the turnover of pharmaceutical firms, a measure which was welcomed by the production firms engaging in many R&D 
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and regional governments have already taken various measures aimed specifically at R&D and 
innovation or financing, and more generally in regard to taxation and employment. However, one 
participant makes the point that the lack of a coherent policy (coherence between federal and 
regional policy and coherence at federal level) is highly negative for Belgium. On the one hand, the 
sector receives support (education, academic research, tax concessions, science policy) while on 
the other hand the results of that research are seriously discouraged at the level of social affairs, 
the budget and public health. 
 
Finally, price regulation emerges as the most negative factor according to the findings. Measures 
that depress prices clearly reduce the incentive for R&D, via lower revenues
48 and hence lower 
investment returns. The price comparisons produced by the pharmaceutical sector indicate that, in 
that connection, Belgian prices for innovative drugs are the second lowest in Europe, after 
Greece
49 
50.  However, it must also be said that, during the period of the survey, debate was raging 
in Belgium over the introduction of the Kiwi model for drugs. That element may have exacerbated 
the negative assessment of this factor: price regulation/low prices in itself plays a role in that 
context, but the pharmaceutical sector also regarded the possible introduction of a tendering system 
and the associated uncertainty as a deterioration in the Belgian investment climate
51. 
 
The assessment of the location factors varies somewhat according to the class of firms. For 
instance, the production firms, which have a larger staff, on average, take a more negative view of 
labour costs than the distribution firms. The latter naturally attach more importance to the proximity 
of the national and European markets than do the production firms, which export much of their 
output, some of it to the rest of the world. In view of the nature of the activities pursued in Belgium, 
the production firms are also more interested in such factors as the availability of infrastructure and 
expertise. Finally, although the proximity of group branches is not generally regarded as very 
significant, that is not so in the case of research centres in class A2. 
 
2.2.8 Funding  sources 
 
The lengthy process facing candidate drugs proceeding through the various stages of development 
and marketing, and the high percentage dropped during the successive research phases, make the 
development of a new drug an expensive and risky business. Investments in pharmaceutical R&D 
therefore entail significant financial risks. Moreover, external funding is often complicated by the 
significant, asymmetric information problems w.r.t. this sector. 
 
It is therefore not surprising that the survey results
52 indicate that the R&D activities conducted by 
the Belgian pharmaceutical sector during the period 2002-2004 were funded almost exclusively 
internally, i.e. by the sale of drugs. Roughly three-quarters of the funds came from the parent 
company or the rest of the group of companies, and one-quarter from the Belgian branches 
themselves. The funding provided by the national government was relatively minimal, amounting to 
                                                       
48  Owing to parallel imports and external reference pricing, these low prices are not confined to Belgium, their effects being 
extended to sales on foreign markets. 
49  A low price level for innovative drugs naturally does not necessarily mean that the general price level for drugs is lower, 
since the product mix also plays a role. In that connection, EFPIA data indicate that the cheaper, generic drugs with a 
market share of around 6 p.c. in Belgium in 2004 have a much lower market penetration than in most other European 
countries. 
50  Other interest groups recently came to the opposite conclusion on the basis of their own calculations. Some people 
consider that these divergent results are attributable to the drugs selected. 
51  The possible effects of reference reimbursement and the "kiwi model" are discussed in more detail in Annex 4. 
52  The answers were weighted according to R&D expenditure. NBB WORKING PAPER 106 - DECEMBER 2006    35 
less than 3 tenths of one per cent of the total resources
53. Analysis by classes of firms also shows 
that this government funding only went to class A production firms, so that it may have been 
specifically aimed at basic research (chart 24). 
 
 
CHART 24  SOURCES OF FUNDING FOR R&D ACTIVITIES 
  (percentages, averages 2002-2004) 
0.3 %
27.6 % 72.1 %





For the production firms and the distribution firms, the relative importance of the parent company 
and the Belgian branch(es) as funding sources proved to be very similar. However, a number of 
individual (production) firms deviate to some extent from this funding pattern: on the one hand, the 
activities of the class A2 research centres (which do not engage in production themselves) are 
wholly funded by the parent company/group of companies, while on the other hand, in the case of a 
number of production companies, almost all the R&D activities are financed by the Belgian 
branches themselves. This naturally applies to independent firms, but some of the production firms 
belonging to a multinational group are also in that situation (table 12). 
 
 
                                                       
53   These figures may take no account of the various indirect support measures – which are more difficult to estimate – 
granted by different governments (tax measures in favour of R&D staff and encouraging R&D investment). 36  NBB WORKING PAPER 106 - DECEMBER 2006 
 
TABLE 12  FUNDING OF THE R&D ACTIVITIES PER CLASS OF FIRMS* 
  (percentages, averages 2002-2004) 
Class* 
   
Belgian 
branch 
   
Group of 
companies 
   
National 
government 
   
Regional 
authorities 
   
Supranational 
authorities 
   
Other 
 




A1 29  71  0.4  0  0  0  100 
A2 0  100  0  0  0  0  100 
A (A1+A2)  27  72  0.4  0  0  0  100 
B 85  15  0  0  0  0  100 
C 100  0  0  0  0  0  100 
Production firms 
(A+B+C) 28  72  0.4  0  0  0  100 
              
Distribution firms (E)  25  75  0  0  0  0  100 
              
Total 28  72  0.3  0  0  0  100 
Source: NBB 
*For a description of the classes of firms, see table 2. 
 
 
2.3  Output data for the R&D activities of Belgian branches 
 
The Belgian pharmaceutical sector puts substantial efforts into R&D in terms of both expenditure 
and personnel, and projects. However, in view of the high failure percentage – not all projects 
actually produce a positive result – regarded as inherent in drug research, these efforts are no 
guarantee of success. 
 
Yet the output of the R&D activities is not so simple to measure. That is particularly true when it 
comes to estimating the specific output of Belgian branches within multinational groups where R&D 
is decentralised and controlled from above. That may be the reason why the response rate in the 
part of the survey devoted to output-related indicators was much lower for most items than for the 
first two sections of the survey, namely the general economic characteristics and the input-related 
indicators. Some of the results concerning the output of the R&D activities therefore need to be 




Since innovative R&D output is difficult to measure and there is no criterion available which can give 
an adequate picture, the survey used various indicators, such as the number of patent applications, 




2.3.1 Patent  applications 
 
Patent figures are commonly used as a yardstick for R&D output, since they offer an indication of 
the innovative output that firms are trying to protect. However, in the case of the pharmaceutical 
industry, it should be remembered that – owing to its specifically time character – this indicator 
provides only a partial picture, and should really be regarded as an intermediate product. In contrast 
                                                       
54  For the same reason, details are not reported per class of firms for all questions. 
55  It is implicitly assumed, as in the survey as a whole, that the innovations primarily concern products rather than 
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to most sectors, the patenting of a pharmaceutical innovation
56 - a molecule which screening has 
shown to be promising - occurs very early on in the R&D process; following granting of the patent, 
the rest of the research process takes another 12 years or so, on average
57. The number of patent 
applications at the start of the research pipeline is therefore much greater than the number of drugs 
that will eventually be put on the market. This is not only because most of the molecules fail to 
survive the various phases of drug research, but is also due to strategic decisions on the part of 
pharmaceutical firms. Defensive patent applications are also filed for molecules on which no further 
research will be undertaken, purely because they are related to a molecule on which research will 
proceed and it might be possible for a competitor to model them
58. 
 
On the basis of the replies from 12 respondents, research activities in Belgium (and elsewhere) in 
the period 2002-2004 resulted in 961 patent applications. Although the response rate to this 
question was low, the global figure for the replies may give a fairly complete picture of the situation, 
because in practice, the applications were filed only by the production firms engaging in basic 
research in Belgium, and the response was complete for firms in the class concerned. However, it is 




CHART 25  PATENT APPLICATIONS IN 
2002-2004 BY APPLICANT 
CHART 26  PATENT APPLICATIONS IN 
2002-2004 BY PATENT OFFICE 
 (percentages)    (percentages) 
67.0 %
33.0 %





Source: NBB  Source: NBB 
 
 
Most of the patent applications were filed by the Belgian branches themselves, and only in a 
minority of cases by another group company or branch: of the total number of applications, 67 p.c. 
                                                       
56  For completeness, it should be mentioned that patents in the pharmaceutical industry do not only concern new active 
substances but may also concern other aspects of a drug (treatment, form of administration, etc.), so that a single drug 
may form the basis of multiple patents. 
57  Owing to the lapse of time between the R&D expenditure and the patent applications, there is little point in calculating the 
“patent intensiveness” of the R&D expenditure on the basis of the survey data, since those only cover a three-year 
period. 
 
58  Van Ex (2001). 38  NBB WORKING PAPER 106 - DECEMBER 2006 
or roughly two-thirds were filed by the Belgian branches (chart 25). If the patent applications 
originating from the firm which represents 71 p.c. of the total are disregarded, then that percentage 
is a great deal higher, namely 96.4 p.c. 
 
 
The breakdown by patent office indicates that only a minority of patent applications were filed with 
the two leading world agencies in that field, namely 27 p.c. with the EPO (European Patent Office) 
and 18 pct. with the USPTO (US Patent and Trademark Office). Conversely, almost 55 p.c. were 
filed with “other” – i.e. national – patent offices, although there appear to be very wide variations in 
practice, depending on the firm (chart 26). The high percentage of "other" is due mainly to a single 
respondent, who specified that this concerned the national offices of several dozen countries 
worldwide: the high absolute number of applications submitted by that particular firm, together with 
the high number of different national offices to which those applications were submitted, would 
seem to indicate that those patent applications largely related to the same underlying “invention”. In 
contrast, the other participants demonstrated a degree of "home bias", applying mainly to the EPO 
(73.4 p.c.) and to a lesser extent the USPTO (24.4 p.c.), while the applications filed with “other", 
more specifically European national offices represent only a few percentage points (2.2 p.c.) of the 
applications. 
 
Not all firms appear to file their patent applications systematically with multiple (global) offices; the 
patents for which this is done are therefore likely to be "high value" patents. 
 
 
2.3.2  Drugs put on the market and their impact 
 
A second output-related indicator polled by the survey concerned the number of drugs put on the 
market as a result of R&D in Belgium (and elsewhere) in the period 2002-2004. 
 
The question here was not confined to new active substances (NAS), an important, traditional 
yardstick for measuring the degree of innovation of the pharmaceutical sector, but referred to all 
types of product innovation, as various sources point out that research on the extension of existing 
product lines – be it by new forms of administration or new indications for existing products – is a 
growing trend. According to data published by the American trade association, the Pharmaceutical 
Research and Manufacturers Association (PHrMA), 80 p.c. of pharmaceutical R&D relates to 
fundamentally new molecules and 20 p.c. to new applications for existing molecules. Furthermore, 
the difference between new and existing molecules need not also reflect differences in the 
innovative value of the drugs, as a frequent criticism is that much of the R&D in the pharmaceutical 
sector is devoted to imitation or duplication of pharmaceutical innovations ("me-too" drugs), rather 
than innovation. Most pharmaceutical innovations are therefore incremental: ground-breaking 
innovations leading to treatment of previously incurable diseases are rare.  
 
In order to cater for market launches and the impact of drugs with varying degrees of innovation, it 
was therefore decided that the survey should make the - admittedly subjective – distinction between 
“new” and "(significantly) improved" products for the market. NBB WORKING PAPER 106 - DECEMBER 2006    39 
 












Effect on employment 
(p.c. of firms) 










              
New*** products  2.9  7.2  5  23  62  15 
            
Significantly improved*** 
products  1.4 6.4  4  55  45  0 
            
Source: NBB 
*  average per product. 
**  average (assumed) investment payback period. 
***  for the market. 
 
 
The findings in regard to marketing as a result of R&D activities in Belgian branches reveal that, 
during the period 2002-2004, each respondent launched on average 2.9 new products and 1.4 
improved products
59 (table 13). 
These averages are entirely consistent with the figures regarded as normal in the sector, since a 
pharmaceutical firm typically launches 1 to 3 important new drugs on the market each year, though 
the chances of success are small. 
 
It is interesting that the survey results also indicate some variations in impact depending on whether 
the products in question are new or improved. For instance, the contribution to turnover is estimated 
as somewhat higher for a new product, at an average of 7.2 pct.
60 as opposed to 6.4 p.c. for a 
significantly improved product (table 13). 
As regards the profitability of pharmaceutical R&D, the sector often mentions that, owing to 
constantly rising research costs combined with downward pressure on prices, it is becoming 
increasingly difficult to recoup the investment costs (plus reasonable recompense for the innovative 
work) with the short effective patent period
61 of 7 to 8 years. 
According to the pharmaceutical sector, only 1 in 3 of the drugs placed on the market will be 
profitable. As already stated, the survey results – particularly the output data – need to be treated 
with great caution, but they do present a more favourable picture. The average assumed investment 
payback time (GTT) appears to be shorter than the effective period of the patent. In the case of 
improved products it averages roughly 4 years, while in the case of new products it is estimated at 5 
years. The fact that it takes a year longer to recoup the investment on a new product than on an 
improved product is doubtless due to the higher research costs entailed in the former case. 
 
Finally, the employment effects are significantly greater in the case of new products: a good 77 p.c. 
of firms reported an increase in employment, with a strong increase in the case of 15 percentage 
                                                       
59  The global figures calculated on the basis of the replies from 16 and 15 respondents respectively totalled 46 new and 21 
improved products. In both cases, the respondents concerned were not always the same ones.  
  For comparison, according to data published by the European trade association, EFPIA, during the three years covered 
by the survey 93 new active substances were launched on the world market. 
60  Averages calculated on the basis of replies by 13 and 10 firms respectively. However, those averages conceal divergent 
percentages for the individual firms, ranging from less than 1 p.c. to over 30 p.c. 
61  The effective period of the patent is the period between the market launch of the drug and the expiry of the patent 
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points. Conversely, in the case of improved products, fewer than half – namely 45 p.c. – of firms 
recorded a (modest) increase in employment (table 12). 
 
2.3.3  Discontinuation of R&D projects 
 
Not all R&D projects actually produce a positive result. According to the pharmaceutical sector, only 
1 in every 5 to 10 thousand screened molecules will actually reach the market as a drug. Although 
the chance of success increases with every hurdle that a molecule passes in the various research 
phases, the risk percentage remains considerable right up to the very last research phase (see the 
box on p. 22). 
 
In the survey, 80 p.c. of respondents stated that they had discontinued projects during the period 
2002-2004. However, the respondents who themselves stated that they were constantly setting up 
R&D activities in a particular phase
62 all had to discontinue research projects prematurely.  
The fact that most firms, namely 50 to 60 p.c., took that decision during the clinical research phases 
must, of course, be viewed in the light of the fact that most Belgian branches are active in that 
particular development phase (table14). 
 
The drug’s ineffectiveness and/or unacceptable side effects were by far the principal reason for 
discontinuing the projects: 80 to 100 p.c. of firms which stopped a project in a particular phase 
indicated those reasons. Corporate strategy, unfavourable sales prospects and the lack of 
government support also appeared to play a role, though to a lesser extent, in both the research 
and development phases (table 14). 
 
 
TABLE 14  PHASES AND REASONS FOR DISCONTINUATION OF THE PROJECT 
   (percentages of firms deciding to discontinue the project in the particular phase) 
 Research
Pre-
clinical  Clinical I Clinical  II Clinical  III
            
a) ineffective drug and/or unacceptable side effects  80  100  78  85  82 
b) poor commercial prospects for the drug concerned  20  0  11  23  18 
c) lack of skilled staff  0  0  0  0  0 
d) high research costs  40  40  0  0  0 
e)  relocation  0 0 0  0 0 
  within the group of companies  0  0  0  15  18 
  outside the group of companies  0  0  0  0  0 
f) lack of tax incentives  0  0  11  8  9 
g) lack of government support  20  40  11  8  18 
h) corporate strategy  20  40  11  15  9 
i) other (specify)  0  20  0  0  0 
 
pm: number of firms deciding to discontinue in this phase as 
p.c. of the total number of firms deciding to discontinue R&D 
projects  25 25 45  65 55 
Source: NBB 
 
                                                       
62  In this connection, see the results for question 2.5, analysed in 2.2.4 "Type of R&D activities". NBB WORKING PAPER 106 - DECEMBER 2006    41 
In contrast, the importance of the other reasons appears to vary according to the research phase. 
For instance, high research costs are a factor which only applied in the research and pre-clinical 
phases, as none of the firms ticked this reason in the clinical phases. Conversely, in these final 
research phases relocation (within the group) was indicated as a factor on several occasions, as 
was the lack of tax incentives. “Other” reasons prompting discontinuation in the pre-clinical phases 
included the rearrangement of priorities (table 14). 
 
 
 42  NBB WORKING PAPER 106 - DECEMBER 2006 
3 CONCLUSION 
 
In 2005 the NBB carried out a survey of the R&D activities conducted in 2002-2004 by 
pharmaceutical firms active in Belgium in the field of research, production and distribution of drugs 
for human use. 
 
In a sector dominated by multinationals, it was not always easy to quantify the exact contribution 
made by the Belgian branches to drug research. The survey results which, on the basis of a 
comparison with the existing (official) sectoral R&D data for Belgium can be regarded as virtually 
exhaustive, nonetheless reveal a number of clear trends. 
 
The Belgian pharmaceutical sector puts a substantial effort into R&D in terms of both the amounts 
invested and the personnel used. The number of projects developed in Belgium is even high 
according to international standards, and confirms Belgium’s leading position in global 
pharmaceutical research. According to the survey findings, more than one new drug launched by 
each firm per year is (partly) the result of R&D conducted by Belgian establishments.  
 
The fact that these research activities may give rise to externalities (relating to expertise) is evident 
from the frequency with which they are outsourced.  More generally, Belgian pharmaceutical firms 
engage in many cooperative projects with other research centres both at home and abroad; this 
primarily concerns hospitals, universities and suppliers (contract organisations), but there is also 
significant cooperation with foreign establishments belonging to the same group of companies. 
 
The expertise available in Belgium, not only in the form of skilled staff but also more specifically in 
the form of knowledge centres, together with the availability of the infrastructure, were cited by the 
pharmaceutical firms as the main reasons for locating their R&D activities in Belgium. Most 
probably, this expertise factor was therefore one of the key advantages for the Belgian 
establishments at the time of the structural changes taking place in the firms in 2002-2004, for the 
survey respondents were unanimous in assessing the effects of those changes as positive for the 
research activities of their own establishment. Factors such as labour costs and government 
intervention in regard to various aspects (price regulation, tax incentives, subsidies and 
administrative procedures) were considered by the participants to have a decidedly negative impact 
on the location of such activities in Belgium . 
 
As well as indicating the importance of Belgian pharmaceutical research, however, the survey 
findings also point to a fragility, which is of course significant with a view to the creation of a 
knowledge economy in accordance with the Lisbon objective. 
 
The breakdown of the answers by type of firm on the basis of type of activities (production, export, 
etc.) conducted in Belgium reveals namely clear differences of emphasis in the type of research 
activities pursued and, consequently, wide variations in the amount of resources devoted to R&D. 
 
In the case of distribution firms, the emphasis is clearly on the final phases of drug research, 
namely the clinical phases. In view of the numerical predominance of those firms, that therefore 
leads to an atypical phase distribution for Belgium in regard to projects in development, with the 
number of projects increasing the later the development phase concerned. The government has 
tried to consolidate Belgium’s position as a host country for clinical trials by creating an attractive NBB WORKING PAPER 106 - DECEMBER 2006    43 
legal framework for this type of research. However, the question is whether Belgium will have 
sufficient advantages to escape the trend towards relocation of clinical trials to low-wage countries; 
in the survey, at least, “relocation (within the group)”was ticked a number of times as the reason for 
discontinuating projects in these research phases in Belgium. 
 
Conversely, the production firms are active in the various stages of drug research, and therefore 
have more molecules, on average, in the Belgian segment of their pipeline. Nonetheless, there are 
only three large production firms permanently active in all R&D phases in Belgium. These firms, 
which all belong to a Belgian company or a company of Belgian origin which was taken over by a 
foreign company, in fact appear to dominate pharmaceutical R&D activities in Belgium, as together 
they account for no less than 85 p.c. of R&D expenditure and 73 p.c. of research staff in the sector 
as a whole. 
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Abbreviations 
 
ANBERD  Analytical Business Enterprise Research and Development (database) 
ANRSE   Analytical Researchers, Scientists and Engineers (database) 
CMR  Centre for Medicines Research International 
EFPIA  European Federation of Pharmaceutical Industries and Associations 
EM  extra muros (extramural) 
EPO  European Patent Office 
EUROSTAT  Statistical Office of the European Communities 
HOKT  Hoger onderwijs van het korte type/ Higher education, short course 
HOLT  Hoger onderwijs van het lange type/ Higher education, long course 
IM intra  muros  (intramural) 
IMS-Health Intercontinental  Marketing Services-Health 
NAI  National Accounts Institute 
NAS  New Active Substance 
NBB  National Bank of Belgium 
OECD  Organisation for Economic Cooperation and Development 
pharma.be  General association of the drugs industry 
Pharmac  Pharmaceutical Management Agency Limited (New Zealand) 
PHrMA  Pharmaceutical Research and Manufacturers Association (US) 
R&D  Research and Development 
RIZIV  Rijksinstituut voor ziekte- en invaliditeitsverzekering / 
National Institute for sickness and disability insurance 
SMEs  Small and medium-sized enterprises 
USPTO  US Patent and Trademark Office 
VA Value  Added 
VOS  Voorschrift op stofnaam / Prescribing by substance name 
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Annex 1 
 
Survey of R&D in the pharmaceutical sector in Belgium 
Preliminary  remark: This survey is collecting data on the R&D activities of the 
pharmaceutical sector in Belgium.  Therefore, when answering the questions, please take 
account only of activities relating to drugs for human use pursued by (all) the Belgian 
branches of your company.  
If none of the Belgian branches of your company engages in any R&D activities in that field, 
it is sufficient to complete items 1 to  2.1. 
Explanatory notes are attached. 
Particulars 
Contact: ................................................................................................................................ 
Telephone or e-mail: ............................................................................................................. 
Belgian branch(es): .............................................................................................................. 
 
1.  General economic particulars concerning (all) Belgian branches 
 2002  2003  2004 
  (x 1000 €)  (x 1000 €)  (x 1000 €) 
1.1 Total  turnover  (amounts in thousand euro)                  
of which (approximate) percentage share represented by:  %  %  % 
a)  drugs produced by the company itself in Belgium                 
b)  drugs produced by subcontractors in Belgium                 
c)  drugs imported from abroad                 
 
 2002  2003  2004 
1.2  Total exports of drugs  (x 1000 €)  (x 1000 €)  (x 1000 €) 
  (amounts in thousand euro)                   
of which (approximate) percentage share represented by:  %  %  % 
a)  drugs produced by the company itself in Belgium                 
b)  drugs produced by subcontractors in Belgium                 
c)  drugs imported from abroad                 
 
1.3 Export  destination  (approximate percentage shares) 2002  2003  2004 
   % % % 
a) neighbouring countries (France, Germany, Netherlands, Luxembourg, UK)                 
b) rest of EU15                 
c) rest of Europe (including the new EU Member States)                 
d) rest of the world                 
 
1.4  Overall staff as at 31 December  2002  2003  2004 
  according to your RSZ [social security] return (in physical units)                   
 
2.  Input data concerning the R&D activities of (all) Belgian branches 
 2002  2003  2004 
2.1  Total expenditure on R&D  (x 1000 €)  (x 1000 €)  (x 1000 €) 
  (amounts in thousand euro)                   
 of  which 
  a) intramural or internal expenditure on R&D (thousand euro)                  
 of  which  (approximate) percentage shares of  % % % 
  1) labour costs                 
  2) other current costs                 
  3) capital expenditure                 
 
  b) extramural or external expenditure on R&D for (all)  
Belgian branches (thousand euro)                 
 of  which  (approximate) percentage shares  % % % 
  1) in Belgium                 
  2) in the rest of the world                 
 
 2002  2003  2004 
2.2  Staff used for intramural R&D  
(in physical units as at 31 December)                   46  NBB WORKING PAPER 106 - DECEMBER 2006 
2.2.1 by function (approximate percentage shares)  % % % 
 a)  managers                 
 b)  researchers                 
 c)  technicians            
  d) other supporting staff                 
 
2.2.2 by level of qualification (approximate percentage shares)  % % % 
  a) holders of a doctorate (or equivalent)                 
  b) holders of a university degree or HOLT diploma                 
  c) holders of a HOKT diploma       
 d)  other                 
 
2.3  In the past 3 years, have there been any significant structural changes (acquisition, merger, 
demerger, sale or department closure) in your company which have had a noticeable effect on 
the R&D activities? 
 yes   no   
 
2.3.1  if yes, indicate the effects on  
  a)  total R&D expenditure of  increase    b) R&D staff:  increase   
  all Belgian branches  decrease   decrease   
 
2.4.a  Total number of molecules currently in development        
 





   I  II  III 
Number of  










2002 (optional)                                     
2003 (optional)                                     
2004                                     
2005 (estimate)                                     
 
2.5  Tick the type, frequency and location of the R&D activities conducted by your firm over the past 
3 years: 
 
  Location of R&D activities 
 Research  Development 
     Pre-clinical  Clinical  phases 












Continuous              
Occasional             
Never             
 
 
2.6  For the whole of your R&D activities, tick the 
frequency of cooperation (including outsourcing) 
with other types of research centres during the past 
3 years   frequent occasional  never 
a) in Belgium:     
  - other pharmaceutical firms        
  - within your own group of companies       
  - from another group of companies       
  - biotechnology firms       
  - universities        
 -  hospitals       
  - suppliers (SME, CRO, CTSO, ...)       
  - other (specify): ...............................................................       
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 frequent  occasional  never 
b) abroad:      
  - other pharmaceutical firms       
  - within your own group of companies       
  - from another group of companies       
  - biotechnology firms       
 -  universities       
 -  hospitals       
  - suppliers (SME, CRO, CTSO, ...)       
  - other (specify): ...............................................................       
 
2.7  Why did your firm locate the R&D activities in Belgium?  
Tick the importance of the following determinants. 
  ((--) highly negative, (-) moderately negative, (0) neutral, (+) moderately positive, (++) highly positive) 
a) Human resources  -- -  0 +  ++ 
  - availability of skilled staff           
  - labour costs           
 
b) Geographical location  -- -  0 +  ++ 
  - proximity to sales markets: national market           
  European market           
  - availability of infrastructure           
  - proximity of other knowledge centres/suppliers           
  - proximity of other group branches           
 
c) Government  -- -  0 +  ++ 
  - tax incentives           
  - national and regional subsidies           
  - protection of intellectual property           
  - price regulation           
  - administrative procedures ( registration, etc.)            
  - legislation on research and (pre)clinical trials           
 
d) Market situation  -- -  0 +  ++ 
 -  competition 
  - on the national market           
  - on the European market           
  - sales prospects for your product range 
  - on the national market           
  - on the European market           
 
e) Other: (specify)………………………………………            
 
2.8  Sources of funding for R&D activities over the past 3 years 
(approximate average percentages) 
 
  a) all the Belgian branches themselves       
  b) parent company or rest of the group of companies      
  c) national government      
  d) regional authorities      
  e) supranational authorities      
  f) other ( specify):………………………………………..        
Total      
 
3.  Output data concerning the R&D activities of all the Belgian branches 
 
3.1  Average number of projects in phase I (determining the initial human dosage) 
leading to approval for the marketing of a drug over the past 3 years       
 
3.2  Total number of patent applications filed in the past 3 years      48  NBB WORKING PAPER 106 - DECEMBER 2006 
 
a) of which 
  - filed by your firm itself      
  - filed by another group company/branch      
 
b) of which 
  - filed with the European Patent Office      
  - filed with the US Patent Office      
  - filed with other patent offices      
 namely  (specify): ....................................................................................................... 
 
3.3  Impact of the products launched on the market in the past 3 years as a result of R&D by type of 
innovation (approximate figures): 
 






effect on employment (e) 
(please tick) 







a)  new products for the market                       
b)  (significantly) improved products for the market                      
1 APP= average assumed investment payback period (in years) 
 
3.4  In the past 3 years, did your firm discontinue R&D - projects? 
 yes   no   
 
3.4.1 If yes, tick the phase and reason for the discontinuation decision: 
 
phase research development 
   pre-clinical  clinical  phases 
reason     I II  III 
a)  ineffective drug and/or unacceptable side effects 
         
b)  poor sales prospects for the drug in question 
         
c)  shortage of skilled staff           
d)  high research costs           
e) relocation           
    within the group of companies            
    outside the  of companies           
f)  lack of tax incentives           
g)  lack of government support           
h) corporate  strategy           
i) other:  (specify)………………………           
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EXPLANATORY NOTES 
 
General remark: This questionnaire uses definitions formulated by the OECD (Organisation 
for Economic Cooperation and Development) in the Frascati manual for R&D surveys.  The 




Research and experimental development (R&D) comprises creative work undertaken on a 
systematic basis to increase the stock of knowledge and the use of this stock of knowledge to 
devise new applications. R&D concerns the following three activities: 
 
Basic research: experimental or theoretical work undertaken primarily to acquire new 
knowledge of the underlying foundation of phenomena and observable facts, without any 
particular application or use in view. 
 Applied  research: research work undertaken in order to acquire new knowledge, directed 
primarily towards a specific practical aim. 
 Experimental  development: systematic work drawing on existing knowledge gained from 
research and/or practical experience, directed to producing new materials, products or 
devices, to installing new processes, systems and services, or to improving substantially 
those already produced or installed. 
  By convention, phases I, II and III of the clinical trials are regarded as R&D; conversely, 
phase IV is only regarded as R&D if it gives rise to further scientific or technological progress.  
However, marketing and process development activities conducted after phase III and before 
permission to launch a drug on the market must all be excluded from R&D. 
 
NB: the questionnaire makes no distinction between basic and applied research. 
 
Total expenditures for R&D: all expenditure for R&D activities conducted in Belgium and/or 
controlled or coordinated from Belgium. 
 
Intramural R&D: Intramural or internal expenditure is all expenditure for R&D within the firm, 
whatever the source of funds.   
Extramural R&D: Extramural or external expenditure is all expenditure for R&D activities conducted 
by third parties for the account of the firm (joint ventures or outsourcing). 
 
Labour costs comprise all wages and salaries on an annual basis and all associated costs or fringe 
benefits. The labour costs of persons providing support services (e.g. security, maintenance and 
computer services) which are not included in the R&D staff data should be excluded; they should be 
recorded under the heading “other current costs”.  
Other current costs comprise all costs for purchases of material, supplies and equipment to support 
R&D activities performed by the statistical unit in a given year and not included under “capital 
expenditure”. They include (pro rata, if necessary): water and fuel; books, journals, reference 
materials, subscriptions to libraries and scientific societies; materials for laboratories; administrative 
and other overhead costs (post, insurance, telecommunications, etc.); support services (security, 
maintenance and computer services). 
 
Capital expenditures are the annual gross expenditures on tangible fixed assets used in the R&D 
activities of the statistical unit. They relate more specifically to land and buildings (land for building 
laboratories, construction or purchase of buildings, including improvements, alterations or 
maintenance work, etc.); instruments and equipment (purchase of major instruments and equipment 




Overall staff: All persons employed directly on R&D should be counted, as well as those providing 
direct support services, such as managers, administrators and clerical staff. 
 
Management: Managers and administrators responsible for planning and directing the scientific and 
technical aspects of R&D. 50  NBB WORKING PAPER 106 - DECEMBER 2006 
 
Researchers: Professionals engaged in the conception or creation of knowledge, products, 
processes, methods and systems and also in the management of the projects concerned. 
 
Technicians: Persons whose main tasks require technical expertise and experience in one or more 
scientific or technical fields. 
 
Others: Skilled and unskilled craftsmen, secretarial and clerical staff participating in R&D projects or 
directly associated with such projects. 
 
 
HOLT: Hoger onderwijs van het lange type/ Higher education, long course 









SMO: site management organisation 
 
CRO: contract research organisation 
 
CTSO: clinical trials supply organisation 
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Annex 2  
 
The importance of the pharmaceutical sector in the Belgian economy: some data on 
value added, employment and R&D expenditure. 
 
Value added and employment
63 
Measured in terms of value added and employment, the pharmaceutical manufacturing industry has 
a relatively minor place in manufacturing industry in general and the economy as a whole. During 
the period 2002-2004, the pharmaceutical industry accounted for an average of 5.4 p.c. of the value 
added of manufacturing industry, and 0.9 p.c. of that of the economy as a whole in terms of GDP. 
As regards employment, the percentages during that period were somewhat lower, at 3.4 p.c. for 
employees in manufacturing industry and 0.6 p.c. of total employees; however, the pharmaceutical 
industry was one of the few industrial sectors which succeeded in maintaining its relative position in 
terms of employment.  
 
TABLE 1  VALUE ADDED AND EMPLOYMENT 
  (in percentages of the total for manufacturing industry) 
 Value  added Employment 
 2002 2003 2004 
Average 
2002-




Manufacturing industry  100.0  100.0  100.0    100.0  100.0  100.0  100.0 
                
Food 13.1  13.7  13.8  13.5  14.3  14.7  15.1  14.7 
Textiles, clothing, footwear  5.3  4.6  4.4  4.8  7.9  7.7  7.4  7.7 
Wood, paper, printing  9.5  9.7  9.0  9.4  9.8  9.7  9.8  9.8 
Chemicals* 23.9  23.5  22.9  23.4  15.9  16.2  16.3  16.1 
 of which: Pharmaceutical industry  5.6  5.6  5.1  5.4  3.2  3.5  3.4  3.4 
Iron and steel  14.1  14.3  15.6  14.6  16.3  16.6  16.6  16.5 
Metalworking 22.8  22.7  21.8  22.5  25.0  24.3  24.1  24.5 
  of which: Audio, video and 
telecommunications 2.7  2.7  2.3  2.6  2.7  2.4  2.2  2.5 
Other 11.4  11.5  12.5  11.8  10.8  10.7  10.7  10.8 
                
  (in percentages of the total for the economy) 
 Value  added Employment 
 2002 2003 2004 
Average 
2002-




Manufacturing industry  16.2  15.6  15.5  15.7  17.7  17.2  16.7  17.2 
                
Food 2.1  2.1  2.1  2.1  2.5  2.5  2.5  2.5 
Textiles, clothing, footwear  0.9  0.7  0.7  0.8  1.4  1.3  1.2  1.3 
Wood, paper, printing  1.5  1.5  1.4  1.5  1.7  1.7  1.6  1.7 
Chemicals* 3.9  3.7  3.5  3.7  2.8  2.8  2.7  2.8 
 of which: Pharmaceutical industry  0.9  0.9  0.8  0.9  0.6  0.6  0.6  0.6 
Iron and steel  2.3  2.2  2.4  2.3  2.9  2.8  2.8  2.8 
Metalworking 3.7  3.5  3.4  3.5  4.4  4.2  4.0  4.2 
  of which: Audio, video and 
telecommunications 0.4  0.4  0.4  0.4  0.5  0.4  0.4  0.4 
Other 1.8  1.8  1.9  1.9  1.9  1.8  1.8  1.8 
                
Source: NAI 
*including rubber and plastics 
                                                       
63 In contrast to the rest of the text, owing to the lack of detailed data for the “wholesale” and “research and development 
activities” branches, this part of the paper relates only to pharmaceutical companies which come under manufacturing 
industry. 52  NBB WORKING PAPER 106 - DECEMBER 2006 
 
However, the above data on value added and employment give an incomplete picture of the 
importance of the pharmaceutical sector in the Belgian economy, since they confine that sector 
strictly to Nacebel code 24.4, or in other words the pharmaceutical manufacturing industry; apart 
from a number of establishments focusing entirely on pharmaceutical R&D activities (Nacebel code 
73), there are numerous branches of multinationals which do not engage in any production activities 
in Belgium, but are involved purely in selling and therefore come under the wholesale sector 
(Nacebel code 51).  
 
To obtain a more complete picture of the impact of the pharmaceutical sector on the Belgian 
economy, account must also be taken of the indirect effects – i.e. the effects entailed for suppliers in 
Belgium. 
 
On the basis of the data obtained from the National Accounts Institute (NAI), using a methodology 
developed by the Bank and based on the input-output tables
64, the indirect effects generated in 
2003 by all the firms registered for the survey were estimated
65. That estimate is not confined to 
first-line suppliers, but extends back indefinitely through the entire supply chain. 
 
TABLE 2  INDIRECT EFFECTS ON VALUE ADDED AND EMPLOYMENT GENERATED BY 
THE PHARMACEUTICAL SECTOR  












   






Of which  
production firms 
 
          
Total indirect effects  1.0  1.1  0.6  0.6 
   of which: first level  0.6  0.7  0.4  0.4 




The calculations reveal that the indirect effects generated by the drugs (for human use) sector on 
the Belgian economy are depressed by the sector’s high import content. The ratio of total indirect 
effects on value added to the direct effects is 0.6; for employment that ratio is slightly higher, 
namely 1.0
66. For the production firms, which for both economic variables account for around half of 
the population surveyed, the ratio between the indirect effects and the direct effects is not 
significantly different from these overall figures. 
 
                                                       
64  This methodology is described in detail in Coppens(2005). 
65  In this connection, see 1.3 “Sample” in the main text of this paper. Since it is not possible to distinguish in the input-
output tables between trade in pharmaceutical products and wholesale in other types of products, the methodology used 
may be slightly less accurate for the distribution firms than for the production firms. 
66  For comparison: in the sector studies, the NBB has already calculated the indirect effects of the motor vehicle and ICT 
sectors. For these sectors, the ratios between indirect and direct effects were 2.3 and 0.5 respectively. NBB WORKING PAPER 106 - DECEMBER 2006    53 
"Business services" is the branch of activity which experiences the most indirect effects, at almost 
60 p.c.
67. More specifically, this primarily concerns coordination centres, consultancies, and 
enterprises involved in legal services and personnel selection.  
After that, the indirect effects are perceptible in the wholesale sector (10 p.c.) and manufacturing 
industry (6 p.c.), within which they are particularly apparent in printing, the preparation of other 
chemicals and, of course, the pharmaceutical manufacturing industry. The remaining effects are 
spread more or less across all the other branches of activity, such as transport, construction, and 





However, the importance of the pharmaceutical sector in the Belgian economy is reflected much 
more prominently and obviously in the R&D expenditure of the Belgian firms. More so than in other 
branches of activity, successful R&D is crucial to the pharmaceutical sector: the importance of this 
sector in terms of the total research efforts of Belgian firms therefore far exceeds the share of the 
pharmaceutical manufacturing industry in purely productive terms (direct value added and 
employment). In view of the considerable extramural R&D activities of the pharmaceutical sector, 
including in Belgium, it can also be assumed that those activities have a significant (indirect) impact 
on certain areas of the Belgian economy. However, this cannot be estimated from the information 
available in the input-output tables.  
  
TABLE 3  R&D EXPENDITURE (INTRAMURAL AND TOTAL) 




Total expenditure (intramural+extramural) 
 
 2002 2003 2004 
Average 
2002-2004  2002 2003 2004 
Average 
2002-2004 
Total firms  100  100 100 100.0  100 100  100  100.0 
Manufacturing industry   79.1  78.6 78.4 78.7  79.2 79.3  79.0  79.2 
               
Food   2.8  2.9 2.9 2.9  2.6 2.7  2.8  2.7 
Textiles, clothing, footwear  1.0  1.0 1.1 1.0  0.8 0.9  0.9  0.9 
Wood, paper, printing  0.5  0.6 0.5 0.5  0.4 0.5  0.4  0.4 
Chemicals* 34.6  37.4 38.1 36.7  40.6 43.7  44.3  42.9 
  of which: Pharmaceutical firms  19.2  21.6 22.6 21.1  28.0 30.7  31.7  30.2 
Iron and steel  5.6  5.6 5.8 5.7  5.5 5.5  5.5  5.5 
Metalworking 31.4  27.6 26.6 28.5  26.4 23.0  22.2  23.8 
  of which: Audio, video and 
telecommunications 16.2  12.6 11.5 13.4  13.5 10.2  9.4  11.0 
             
Source: FPS Science Policy 
* including rubber and plastics 
 
 
The Belgian pharmaceutical sector appears to spend substantial amounts on R&D, not only 
according to comparisons between sectors but also in international (European) terms. According to 
                                                       
67  For completeness, it should be mentioned that, in the national accounts, some firms are assigned to sector classes 
which do not always correspond to the sector classes in which they submit their annual accounts. 
68   For a proper understanding, it should be remembered that the sectoral data on R&D expenditure are ANBERD-
estimations; the data for the manufacturing industry thus in fact concern a broader aggregate. More specifically for 
pharmaceutical firms, this implies - contrary to the previous section of this annex where the data on value added and 
employment only concerned the pharmaceutical manufacturing- that the data in this section als incorporate R&D 
expenditure by pharmaceutical distribution firms and research centres. In this connection, see also footnote 10. 
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figures for 2004 supplied by the European umbrella organisation of the pharmaceutical sector 
associations, EFPIA, Belgium put significant efforts into research not only in relative terms – i.e. in 
comparison with output and the size of the national market – but also in absolute terms, as there 
were only some large countries such as the UK, France, Germany and Switzerland that preceded 
Belgium in the ranking of R&D expenditure. 
 
 
CHART 1  R&D EXPENDITURE OF THE 
PHARMACEUTICAL 
SECTOR IN PERCENTAGES 
OF OUTPUT  
  CHART 2  R&D EXPENDITURE OF THE 
PHARMACEUTICAL SECTOR IN 
PERCENTAGES OF SALES ON 
THE NATIONAL MARKET 




































Source: EFPIA    Source: EFPIA 
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CHART 3  R&D EXPENDITURE OF THE EUROPEAN PHARMACEUTICAL SECTOR IN 
2004 
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Annex 3 
 
Profitability of companies in the pharmaceutical sector 
 
The profitability of all firms registered for the survey was calculated on the basis of the annual 
accounts filed with the NBB’s Central Balance Sheet Office
69. 
 
The "(net)return on equity", or in other words the companies’ ability to make a profit, is presented in 
the form of a median, as this yardstick refers to the situation of the central firm – i.e. 50 p.c. of 
companies, regardless of their size, have a ratio which is above this median value, while the other 
50 p.c. have a ratio below it – and therefore reflects the picture for the population as a whole to a 
greater extent than the globalisation criterion
70, since the latter – particularly at the level of the 
business branches – is more influenced by (exceptional) movements within (large) individual 
companies. As is usual in the case of the ratio analysis, a distinction is made between large firms 
and small/medium-sized enterprises (SMEs), as the method of financing and the financial position 
of firms differ according to the size of the business. 
 
 
CHART 4  RETURN ON EQUITY  






1996 1997 1998 1999 2000 2001 2002 2003 2004
Pharmaceutical sector (Large firms) Pharmaceutical sector (SMEs)
Manufacturing industry (Large firms) Manufacturing industry (SMEs)





The calculations reveal that the median values for both types of firms tended to decline overall 
during the period 1996-2004. The large firms generally had a higher level of profitability than the 
SMEs: during the period 2002-2004, or in other words the period of the R&D survey, the difference 
between the two averaged over 5 percentage points. 
                                                       
69  In this connection, see 1.3 “Sample” in the main text of this paper. The calculations concerning profitability and failure 
prediction naturally took account only of the data for firms which file annual accounts with the NBB. 
70  The globalisation is obtained more specifically as the ratio of the sum of the numerators to the sum of the denominators. NBB WORKING PAPER 106 - DECEMBER 2006    57 
 
TABLE 4  RETURN ON EQUITY 






   2002 2003 2004 2002 2003 2004 
        
Pharmaceutical  sector  12.4  7.6 7.5 3.7 3.2 3.2 
        
Manufacturing  industry  7.4 9.5  11.6  4.6 5.3 6.7 
        
Total non-financial 
corporations  6.9 8.8  11.0  5.1 6.0 6.8 




Comparison of the profitability of the pharmaceutical sector with other branches of industry reveals 
that the downward trend in the pharmaceutical sector was in contrast to the rather upward trend 
seen for manufacturing industry as a whole and for non-financial corporations during the past 
decade. As a result of that divergence, profitability in the pharmaceutical sector is now lower than in 
manufacturing industry or non-financial corporations as a whole – in contrast to the situation a few 
years ago. Although it is generally true that large firms have higher profitability than SMEs, the 
difference appears to be more marked in the pharmaceutical sector than elsewhere over the period 
considered ( table 4). 
 
In order to assess the financial risks of the firms, the NBB has developed an internal failure 
prediction model
71. This model classifies firms into four risk classes on the basis of eight variables 
concerning their financial situation. Classes 3 and 4 correspond to firms in difficulty and in serious 
difficulty respectively. A firm in either of those classes has a risk of failure (within 3 years) which is 
respectively 3-4 times or over 10 times greater than the average. 
 
However, this classification of firms has to be interpreted with caution. Only a very small percentage 
of the firms will actually become bankrupt or be subject to judicial composition. The classification 
should really be viewed as an indication of financial health rather than a prediction of failure in the 





                                                       
71  The methodology of this model is explained in detail in Vivet (2004). 
72  Apart from bankruptcy, these difficulties may lead to delays in the repayment of debts or the payment of suppliers, 
redundancies, restructuring or even the cessation of activity. However, Belgian firms which are part of large 
multinationals will often find that, if they are in difficulty, the parent company is prepared to offer them financial support, 
at least for a time. 58  NBB WORKING PAPER 106 - DECEMBER 2006 
CHART 5  COMPANIES IN (SERIOUS) FINANCIAL DIFFICULTIES  
(CLASSES 3 AND 4) 
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Generally speaking, it can be said that the percentage of non-financial corporations in (serious) 
difficulties is slightly higher for SMEs than for large firms. In the pharmaceutical sector, this 
difference is much more marked since the sector contains relatively fewer large firms in financial 
difficulties, but the percentage of SMEs with financial problems is clearly higher than the general 
average for SMEs (chart 5). 
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Annex 4 
 
Reference reimbursement for drugs and R&D 
 
The Belgian government has taken various measures in recent years to control health care 
expenditure, and more particularly expenditure on the reimbursement of drugs. Some of those 
measures, such as price freezes and cuts, have a direct impact on drug prices. In contrast, the 
reference reimbursement system for eligible drugs, introduced on 1 June 2001 to encourage the 
prescription of cheap drugs, has an indirect effect on prices, as a general rule. Since the entry into 
force of this system, various additional measures have been passed, including the Health Act of 27 
April 2005, which are in fact intended to reinforce and extend the reference reimbursement system. 
 
However, reference reimbursement for drugs is controversial for a number of reasons, including the 
elimination of incentives for innovation. This would apply, in particular, under the rigid New Zealand 
prototype, advocated as a model for Belgium in recent years on account of its drug tender 
technique.  
This annex therefore describes the system of reference reimbursement and the possible variants. 
On the basis of an analysis of the economic literature on this reimbursement system, it gives a brief 
account of the system’s reported effects; of course, the impact on R&D receives particular attention. 
 




Reference reimbursement for drugs is a system in which equivalent products are grouped together 
in classes, and the reimbursement for all products in the same class is based on the same 
reference price. Under such a reimbursement system, the producers are therefore free to set their 
prices – in contrast to a pure price control system; however, leaving aside the usual non-refundable 






A number of industrial countries are now applying a form of reference reimbursement. However, the 
existing systems vary considerably in two respects, namely the criterion used for grouping 
equivalent drugs and the determination of the reference price. 
 
As a rule, distinction is made between three different types of reference reimbursement according to 
what is meant by the term “equivalence”.
73 
 
The first type uses the narrowest definition, namely chemical equivalence: only drugs with the same 
chemically active component are grouped together. This type is often also referred to as "generic 
equivalence". 
The second type of reference reimbursement is based on pharmacological equivalence, and 
therefore groups drugs on the basis of chemically related ingredients which have the same effect. 
Finally, the third type uses the broadest criterion for grouping drugs, namely therapeutic 
                                                       
73  The literature also refers to these types as “phases”, although there need not be any chronological link between them. 60  NBB WORKING PAPER 106 - DECEMBER 2006 
equivalence. Here, drugs for the same disorder are put together in one class, but need not be 
chemically or pharmacologically equivalent.  
 
When defining equivalence, there is an essential point of difference between the reference 
reimbursement variants applied in the different countries, in whether or not drugs under patent are 
included in the classes of drugs listed. As a result of the nature of the definition itself, generic 
substitutes only apply to non-patent drugs, namely products on which the patent has expired and 
their generic equivalents,
74 and this option applies only to the second and third types. 
 
The reference price is the fixed basis for reimbursement applicable to all drugs in the same class or 
sub-class. That price is generally based on a particular point in the range of producer prices (e.g. 
the minimum, the median, the average…). If the reference price is determined by comparing prices 
within one country, it is called an internal reference; in the case of external reference, prices for the 
same or similar drugs in other countries are considered
75.  
 
In 1989, Germany became the first country to introduce a reference reimbursement system. Since 
then, various other industrial countries have introduced one variant or another, including the 
Netherlands (1991), Sweden (1993), Denmark (1993), New Zealand (1993), the province of British 
Colombia in Canada (1995), Australia (1998), Italy (1996), Spain (2000) and Belgium (2001). As a 
result of these examples and on the recommendation of the World Bank, this model was also 
introduced in a number of Central and East European economies. Norway, which introduced the 
system in 1993, abandoned it after assessing the results in 2001, while Finland, which rejected the 
system in the last decade, is now reconsidering its introduction. In the past few years, a number of 
countries which apply a reference reimbursement system have made changes to the system or plan 
to do so in the near future. Subject to certain reservations
76, the table below shows the current 
situation regarding the characteristics of the various systems. 
 
                                                       
74  A generic is a drug which contains the same active substance, in the same dose and form as the orginal branded drug, 
and has the same bio-availability, i.e. is absorbed in the same way by the human body. Generics cannot be placed on 
the market until the patent on the original branded drug has expired. 
75  In the case of therapeutic reference systems which group together drugs of differing composition, it is of course 
necessary to determine substitute dosages – i.e. dosages for different drugs having the same effect for patients – before 
determining the reference price. 
76   The information in the table is provided subject to certain reservations because the characteristics of the reference 
reimbursement system used in one particular country often differ according to the source, and inquiries to the various 
foreign institutions did not always produce an answer. However, it is worth mentioning that the European Commission is 
currently running a project (Pharmaceutical Pricing and Reimbursement Information) which aims to ascertain the 
characteristics of the drug pricing and reimbursement policy applied in the various European Union Member States. 
However, the results of this project will not be available until spring 2007.  NBB WORKING PAPER 106 - DECEMBER 2006    61 
TABLE 5  OVERVIEW OF REFERENCE REIMBURSEMENT SYSTEMS 
 












           
Australia 1998  pharmacological 
equivalence 
yes  lowest price in the 
group 
 
          
Belgium 2001  chemical 
equivalence  
no  30 p.c. below the 
price of the original, 
branded drug 
-possibility of extending groups (other 
dosages and forms of administration for the 
same active substance/other active 
substances for the same/similar 
indications) 







yes  lowest price in the 
group 
 
          
Denmark 1993  chemical 
equivalence  
no  lowest price in the 
group 
- before 2005: average of lowest 2 prices in 
the group 
          
Germany 1989  therapeutic 
equivalence 
yes  median price  
(on the basis of a 
regression model) 
-initially chemical equivalence; since 1992 
and 1993 respectively, pharmacological 
and therapeutic equivalence 
-(new) patent medicines excluded in the 
period 1996-2003 
-exceptions based on the innovation 
protection clause 
          
France 2003  chemical 
equivalence 
no (1)   
          




no weighted  average 
of generic prices 
 
          
Netherlands 1991  therapeutic 
equivalence 
yes  average price in the 
group 
 





yes  lowest price in the 
group/sub-group 
- also sole supply tenders and cross-
therapeutic deals 
          
Norway 1993-2001  chemical 
equivalence 
no  lowest price in the 
group + 5p.c. 
-1998: extended to parallel imports 
-1999: extended to other forms of 
administration 
          
Portugal 2002  chemical 
equivalence 
no highest  generic 
price 
 
          
Spain 2000  chemical 
equivalence 
no  highest price in the 
group -10 to 50 p.c. 
 
          
Sweden 1993-2002  chemical 
equivalence 
no  lowest price in the 
group +10 pct 
 
Sources:  among others Danzon (2003), Lopez-Casasnovas & Puig-Junoy (2001), Mestré-Ferrandiz (2003) and EU (Pharmaceutical 
Pricing and Reimbursement Information project) 
 
(1) Information on the exact determination of the reference price was not supplied, but would be linked to the prices for generics. 
(2) Catalogued by Mestré-Ferrandiz (2003) as pharmacological equivalence. 62  NBB WORKING PAPER 106 - DECEMBER 2006 
Reference reimbursement in New Zealand 
 
In 1993, reforms in the New Zealand health sector led to the establishment of Pharmac 
(Pharmaceutical Management Agency Limited), an independent public body with the specific 
objective of improving control over government expenditure on drugs. In that context, Pharmac 
manages the list of subsidised drugs (Pharmaceutical Schedule), and takes decisions on the 
inclusion of products in the list, the levels of subsidy and the guidelines and conditions for 
prescribing the products. 
 
Pharmac uses a system of reference prices for drug reimbursement. The detailed reference classes 
and the strategies applied by Pharmac to keep costs under control appear to make the New 
Zealand model a rigid variant of the system: the drugs eligible for reimbursement in New Zealand 
are subdivided into therapeutic groups and subgroups
77, without a distinction between non-patent 
and patented products. The reference prices correspond to the lowest price in each sub-group
78. 
New (innovative) drugs are only reimbursed if they are included in the existing sub-group and the 
price is set below the current reference price for that sub-group
79. 
 
In addition to the reference price mechanism, Pharmac uses a range of other strategies to keep 
expenditure under control. Those strategies are aimed both at the demand side (e.g. national 
guidelines on the prescribing of certain drugs; only specialists may prescribe certain drugs, etc.) 
and the supply side of the market. On the supply side the main instruments are "cross product 
deals" and "tenders". "Cross-product deals" are agreements with pharmaceutical firms whereby 
new drugs are included in a particular sub-group and reimbursed in exchange for reductions in the 
prices of existing products in other sub-groups (leading to a lower new reference price in the latter 
groups)
80. The tender technique
81 is used for non-patent drugs
82: in exchange for a low price, 
producers then gain a larger market share, generally for 3 years (preferred supplier contract), or the 
whole market (sole supply contract), in which case all competitors are removed from the 
reimbursement list. It is particularly this last aspect of the New Zealand drugs policy, namely the 
tender technique, that is known in Belgium as the "kiwi model". 
 
 
Reference reimbursement in Belgium 
 
On the basis of such factors as therapeutic effectiveness and social importance, drugs eligible for 
reimbursement in Belgium (branded drugs, generics and copies) are divided into five categories 
linked to a particular level of reimbursement. Since 2001, that reimbursement has been based on 
the principle of reference reimbursement, whereby the government aims to encourage the 
prescribing of cheap drugs: the basis for reimbursement of an original drug for which a cheaper 
version is available (often a generic or copy) is cut by 30 p.c.
83. There are now generics available 
                                                       
77  This concerns respectively drugs used for the same or a similar disorder, and drugs which produce the same or similar 
effects for the treatment of the same or similar disorders. 
78  Although the manufacturers can, in principle, charge more than the reference price, Pharmac could in some cases 
decide to refuse reimbursement of the product.  
79  New drugs can also be reimbursed if they are the subject of a special deal ( cross-product, price/volume deal,..) with 
Pharmac; see below. 
80  In the specific case of new drugs, Pharmac also uses price/volume contracts for limited launches (e.g. for a specified 
target group). 
81  Roughly one-third  of the drugs listed in the Pharmaceutical Schedule form the subject of such tenders. 
82  According to PhRMA, however, some tenders have also concerned patented drugs.  
83  At the time of accepteance for reimbursement, a generic must be cheaper than the original drug; that lower price is due 
mainly to the absence of R&D costs. At the time of introduction of the reference reimbursement system, the reduction 
was only 16 p.c., but was later increased to 20 p.c., then 26 p.c., and 30 p.c. since 1 July 2005. NBB WORKING PAPER 106 - DECEMBER 2006    63 
for around 300 original drugs. In the case of drugs for which there are no generic variants, the non-
refundable element is still calculated, as it always was, as a percentage of the actual cost 
(consumer price). 
 
As part of further economy measures, the government made provision, in the Health Act of 27 April 
2005, for the possibility of extending reference reimbursement to all dosages and all forms of 
administration for the active substance included in the system, and extension – via a procedure for 
each class – to drugs containing other active ingredients for which the indications are the same or 
similar. It also introduced the "kiwi-light" model, based on the New Zealand tender technique, but 
this model will first be tested on cholesterol-reducing drugs – at almost 10 p.c. of expenditure, these 
are the largest category in the pharmaceutical budget – before being applied to other categories of 
drugs. However, the Belgian version of the model varies from the New Zealand original in several 
respects. Indeed it uses market inquiries instead of a tender; in contrast to what happens in New 
Zealand, the reimbursement here will not be restricted to the cheapest drug, and that drug does not 
acquire a monopoly, although it will receive more by way of reimbursement than the more 
expensive competitors. There are two variants of this “differential” reimbursement. The first variant 
consists in maintaining the status quo for the cheapest drug and demoting the other drugs by one 
reimbursement category ( with the same price and basis of comparison). In the second variant, the 
basis of reimbursement of all drugs is reduced to the cheapest. The first variant was chosen for the 
cholesterol- reducing drugs: more particularly, this means that from 1 January 2007 the rate of 
reimbursement for the cheapest medicinal product found in the survey will be 75 p.c., while for the 
other drugs only 50 p.c. (of the reimbursement basis) will be reimbursed by the health insurers. 
However, in contrast to the original draft law, the Belgian system is confined to non-patent drugs
84. 
Nevertheless, the length of time for which the reimbursement advantage will apply is currently still 
unclear. 
 
In line with the reference reimbursement, the Belgian drugs policy also has measures aimed 
specifically at the demand side. For example, since 1 October 2005 it has been possible to 
prescribe by substance name (VOS), and the prescribing practice of doctors is monitored: they 
have to prescribe generics in 27 p.c. of cases
85. 
 
                                                       
84  In the case of cholesterol-reducing drugs, the system applies to only a minority of the available medication, since around 
70 p.c. of the drugs are patented. 
85  Despite the various government measures in recent years to encourage the sale of cheap drugs, the penetration of 
generics has remained remarkably low in Belgium: according to data from the umbrella organisation, EFPIA , generics 
accounted for only 6 p.c. of total sales (in terms of value) on the Belgian market in 2004, one of the lowest percentages 
in Europe. However, according to figures announced by the government, generics recorded a significant increase in their 
market share in mid 2006, and this was attributed to measures taken in 2005. 64  NBB WORKING PAPER 106 - DECEMBER 2006 
 




The obvious aim of reference reimbursement is to maintain control of expenditure on prescription 
drugs, via reimbursement by the third party bearing the cost. 
The underlying reasoning here is that the pharmaceutical market is less price-sensitive on the 
demand side
86 and there is a degree of market power on the supply side
87, so that it is necessary to 
encourage competition in order to reduce prices. It is assumed that the patients subject to the 
reference reimbursement system become more price-sensitive since they themselves have to pay 
the excess on top of the reference price, while firms will cut their prices in order to safeguard their 







Although the basic idea behind reference reimbursement is attractively simple, the literature draws 
attention to the potential weaknesses of such a system, particularly if it involves more than just 
generic equivalence. 
 
However, experience of this system in other countries cannot be simply assumed to be generally 
applicable. Not only do the exact details of the system vary from one country to another, the effects 
of such a system cannot be precisely ascertained, since there are generally various other drugs 
policy measures in force on both the demand and the supply side in the countries concerned
90. In 
considering the findings in the literature, it is therefore necessary to focus on the general direction 




One general finding which emerges from the empirical literature is that the system of reference 
reimbursement is not in itself an effective means of maintaining control over the drugs budget. In 
the short term, this system may reduce expenditure on drugs, but in the medium to long term 
additional measures are needed to achieve that. 
 
There are various reasons why a reference reimbursement system does not succeed (permanently) 
in achieving its objective. Not only are the effects on price competition less significant than hoped, 
the system also targets only one component of expenditure, while volume and changes to the 
prescription mix are not addressed, or are even encouraged in the wrong direction (cf. infra). 
 
                                                       
86  This lower price sensitivity is due to problems of asymmetric information among both physicians and patients, and to the 
existence of systems of reimbursement by a third payer. 
87  Since not all firms are active in all therapeutic fields, there is likely to be oligopolistic competition on the drugs market, 
with comparable but not totally identical products. 
88  Lopez-Casasnovas and Puig-Junoy (2001). 
89  Danzon (2001); Lopez-Casasnovas and Puig-Junoy (2001);Dijkgraaf (2004). 
90  Danzon and Ketcham (2003). NBB WORKING PAPER 106 - DECEMBER 2006    65 
The countries where this system was introduced found that prices initially tended to fall to the 
reference level for the class in question
91. However, various authors remark that setting a reference 
level does not automatically engender competition below that level
92. A number of studies
93 also 
state that the relevant competition on the drugs market tends to take place between the branded 
drug and the generic version of the same active substance, rather than between products which are 
therapeutic alternatives
94. Studies
95 relating to Sweden have also shown that the savings achieved 
in the short term may be at the expense of competition in the long term: owing to lower profitability 
following introduction of reference reimbursement, there was a 50 p.c. decline in the number of 
generics entering the market. The Norwegian report evaluating the reference reimbursement 
system explicitly states that the competition effects are minor, because demand is not price-
sensitive
96. A reduction in the reimbursement price does not in fact always guarantee the 
substitution of a cheaper drug. The price-sensitivity of demand depends mainly on the price-
sensitivity of each of the parties involved in the decision-making process: apart from 
consumers/patients, it is therefore also necessary to encourage the physicians and pharmacists to 
bring about a change in demand. But in practice, it is found that the producers compete not only on 
price but also in other ways, such as by influencing the prescribing behaviour of doctors, in order to 
maintain/increase their market share
97. 
 
Depending on the range of products covered by the system, the reference prices often apply to only 
a small proportion of the drugs eligible for reimbursement. Moreover, producers can try to minimise 
the effect of the reference prices on their total income by increasing the prices of their drugs not 
covered by the reference system; what is more, new and more expensive drugs are constantly 
coming onto the market. The effect of reference reimbursement on the general drug price level is 
therefore not all that clear. Indeed, it was repeatedly found that not only did the price increase, so 
did the market share of the products not covered by the reference system; in particular, there were 
noticeable shifts towards new/improved drugs – which were therefore more expensive because they 
were protected by a patent. This phenomenon was also seen in Belgium after the introduction of the 
reference reimbursement system
98. Finally, a reference reimbursement system offers no intrinsic 
incentives for addressing the volume of medication. 
 
Side effects: distribution effects, health effects and substitution within health expenditure 
 
Reference reimbursement is expected to produce significant side effects as a result of the assumed 
homogeneity of drugs in the same class. However, these products can generate a varying 
therapeutic response in patients (e.g. effectiveness, interactions or side effects) so that they are not 
considered equivalent. Naturally, the likelihood of such variations is greater the broader the class 
definition, as in the case of therapeutic substitution. As a result, reference reimbursement can lead 
to unfair discrimination against vulnerable groups (the elderly, the chronically sick,...) in two ways: 
first, in the financial sense, if they decide not to substitute cheaper products and are therefore liable 
in full for the extra cost associated with the higher priced drugs (distribution effects); second, in 
                                                       
91  The importance of the specific context and implementation of the concept in the assessment of reference reimbursement 
is evident in this connection from the example of Germany. Here it was found that some generic producers raised their 
prices to the reference level, as that level was determined as the statistical median.  
92  Brouwer and Rutten (2001); Danzon (2001). Lopez-Casasnovas and Puig-Junoy (2001) actually state: “ Even so, it has 
to be said that RP in New Zealand had failed by international standards to deliver low prices for generics” (p. 28).  
93  Pavcnik(2002); Danzon and Ketcham (2003). 
94  Conversely, a number of studies point to the existence of a “generic paradox”, whereby the average prices of the 
branded products tended to increase following the introduction of the generics, without any loss of market share. 
95  Jönnson (1994); Ekelund (2000) 
96 ECON  (2000). 
97 Dijkgraaf  (2004). 
98  RIZIV (2004); Simoens (2005). 66  NBB WORKING PAPER 106 - DECEMBER 2006 
regard to the health risk if – on cost grounds – they do decide to substitute cheaper drugs which 
may be less effective for them (health effects). The additional health problems which might result 
could ultimate give rise to an increase in expenditure on other aspects of health care (GP 
consultations, hospital admissions, etc.) or even additional consumption of medication (substitute 
health expenditure). 
 
 Side effects on R&D 
 
However, reference reimbursement is also controversial on account of the potential impact on R&D. 
Yet it is noticeable that, in contrast to the price responses by producers, the implications for R&D 
are rarely examined in depth by the economic literature, and there is hardly any theoretical or 
empirical backing for the points of view. Although the various authors appear to agree that effects 
do exist, there is not always a consensus on the direction of the effects. 
 
It appears to be generally accepted that the effects of reference reimbursement on R&D in the case 
of generic substitution are minimal, since patent protection applies and there are therefore still 
incentives for R&D. However, if patented drugs are also included in the reimbursement system, 
there appears to be a greater threat to future R&D
99. The reference price used in such a system is 
often the price of a generic product, and – in view of the limited R&D expenses for generics – that is 
often close to the production cost. But for the research-intensive pharmaceutical industry, such a 
price means erosion of the economic value of the patent, since such pricing does not allow for any 
compensation of the R&D costs incurred
100, destroying the incentive for R&D and innovation. In that 
case, reference reimbursement would influence not only the volume of R&D investments,  but also 
the type of research carried out and access to new drugs.  
 
Since the innovative pharmaceutical industry obtains most of its investment resources from its own 
(predicted) income, a lower profit margin under reference prices means a smaller budget available 
for research activities
101. However, according to some studies, the level of R&D investment is 
significant for the rate at which new drugs are invented, so that a sub-optimum investment level 
would mean fewer new products in the longer term
102. A study commissioned by the US Department 
of Commerce
103 calculated, for example, that price deregulation in 11 OECD countries
104, including 
Belgium, would lead to an increased R&D budget which, taking account of the current allocation of 
the research budgets by type of research, would yield 3 to 4 additional new molecules each year. In 
the specific case of Belgium, it may be that, owing to the small size of the drugs market, the 
incomes received here have little impact on the overall, worldwide R&D budgets of the research-
intensive multinational pharmaceutical industry. 
In a global market, however, the impact of a national pricing policy is not confined to national 
territory: by means of parallel imports and external reference, the lower prices – and hence also 
their effects on the research budget – can be transferred to other countries. There is then a real 
danger that the research-intensive pharmaceutical industry may respond by winding down its 
research activities in the countries concerned and/or postponing market launches in countries which 
adopt a "free rider" attitude towards pharmaceutical R&D. A number of studies have already 
                                                       
99  In some cases, the exclusion of patented drugs from the reference reimbursement system is only partial (e.g. only 
patents relating to active substances, not processes, use or formulas). 
100  According to Danzon (1998), those costs account for 30-50 p.c. of the drug price. 
101  Some authors qualify this argument to a substantial degree, as pharmaceutical firms are multi-product companies and 
their total income/profits need not decline if some of their sales fall outside the reference reimbursement system. 
102  Kessler (sd); Lopez-Casasnovas and Puig-Juoy (2001). 
103  US Department of Commerce (2004). 
104  Apart from Belgium, this concerns Australia, Canada, France, Germany Japan, Italy, the Netherlands, Spain, Sweden 
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indicated that, under systems with the strictest reference prices, fewer new drugs come onto the 
market than under less strict systems, with the inevitable potential implications
105. In the same 
connection, it was found that the drugs coming onto the market are fewer in number and slower to 
arrive where prices are lower, where the countries concerned are smaller, where parallel exports 
are greater and where the pharmaceutical company does not have an branch
106. 
 
The effects of reference prices on R&D are nevertheless not confined to the level of the research 
efforts, but also concern the nature of the research carried out. However, the literature contains 
totally conflicting views on this. 
 
One view states that under reference prices there will be less investment in gradual innovation – 
small but potentially significant improvements, compared to existing drugs for a particular disorder – 
because those drugs will have to compete with the existing branded products and generics, which 
ultimately creates a risk of concentration on obsolete products within a group of drugs. However, a 
break-through innovation creates a new market, and can therefore escape the reference price. But 
since a breakthrough is associated with a lower chance of success and higher development costs, 
the risk of higher prices for new drugs would increase in this scenario. 
 
The other view states that, since the expected revenues under reference reimbursement decline, 
there will actually be a shift towards imitative rather than innovative drugs, since these imply smaller 
R&D budgets. 
 
As we know, this problem of choice was in only one recent paper addressed in a formal way, based 
on a simplified setting  specifically for the Spanish (generic) variant of reference reimbursement
107. 
The author concluded that, although the switch to a reference price system may have a significant 
influence on the investment decision, the outcome is unclear: the (size of the) difference in R&D 
costs for developing the two types of new drugs is not the only factor; the market power of the 
company also plays a role (the greater its market power, the greater the likelihood of incremental 
innovation). 
 
                                                       
105  Danzon and Ketcham (2003); the Belgian Senate (2005). 
106  Danzon, Wang and Wang (2003). 
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